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Abstract 
Aneuploid genomes, characterized by unbalanced and diverse chromosome stoichiometry 
(karyotype), are associated with cancer malignancy and drug-resistance of human pathogenic 
fungi.  My PhD projects studied three aspects of aneuploidy that are logically linked to each other: 
the production of aneuploidy by environmental stress; the impact of the heterogeneous 
aneuploidy population generated by stress on adaptability; the potential therapeutic strategy 
towards these heterogeneous aneuploidy populations with high adaptability, a root for the 
clinical challenge in treating aneuploidy diseases such as cancer. 
 We investigated whether pleiotropic stress could induce the production of aneuploidy in 
budding yeast.  We showed that while diverse stresses can induce an increase in chromosome 
instability (CIN), proteotoxic stress, caused by transient Hsp90 inhibition or heat-shock, 
drastically elevated CIN to produce karyotypically mosaic cell population.  The latter effect is 
linked to an evolutionarily conserved role for Hsp90 chaperon complexes in kinetochore 
assembly.   
 We found the induction of aneuploidy population potentiates adaptability. Continued 
growth in the presence of Hsp90 inhibitor resulted in emergence of drug-resistant colonies with 
chromosome XV gain.  This drug-resistance phenotype is a quantitative trait involving copy 
number increases of at least two genes located on chromosome XV.  Short-term exposure to 
Hsp90 stress, which produced an aneuploidy population with heterogeneous karyotypes, 
potentiated fast adaptation to unrelated cyto-toxic compounds through different aneuploid 
chromosome stoichiometries.   
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 We designed an evolutionary trap to harness the adaptability of heterogeneous 
aneuploidy populations with high adaptability.  Using a combination of experimental data and a 
general statistical model, we showed that the degree of phenotypic variation, thus evolvability, 
escalates with the degree of overall growth suppression irrespective of stress mechanisms. Such 
scaling explains the challenge of treating aneuploidy diseases with diverse different karyotypes 
by imposing a single mode of inhibition, yet specific karyotype features can be highly targetable.  
Motivated by this finding, we proposed an “evolutionary trap” targeting both karyotypic diversity 
and fitness of the population.  This strategy entails a selective condition “channeling” a 
karyotypically divergent population into one with a predominant and drugable karyotypic 
feature.  We provided a proof-of-principle test with mechanistic explanation in budding yeast 
and demonstrated the potential efficacy of this strategy toward aneuploidy-based azole 
resistance in the human pathogen Candida albicans.   
 
Karyotype channeling also happens naturally in tumors, which is resulted from adaptation to the 
tissue micro-environment and/or the need for oncogenic transformation.  This natural karyotypic 
selection may be leveraged by drug treatment targeting the selected karyotype feature.  Thus, 
the strategy proposed here may be utilized for designing a class of treatment regime distinct from 
current therapies.   
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Chapter 1: Introduction -- Aneuploidy, an Type of Widely 
Observed Mutations  
The contents are adapt from: 
Chen G*, Rubinstein B, Li R. 2012. Whole chromosome aneuploidy: big mutations drive adaptation by 
phenotypic leap. Bioessays 34: 893-900. (Cover story)  
* correspondence author 
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 Aneuploidy is a widespread genetic variation in nature  
 
Error in genome transmission is usually harmful to the fitness of an individual cell or organism, but in a 
population with a large number of individuals, imperfect genome transmission produces genetic 
variants, which are essential for adaptive evolution under selection.  The most commonly considered 
genetic variants during evolutionary processes are point mutations.  Chromosome segregation also 
produces genetic variants, not in single gene sequences but in the copy number of chromosomes, which 
contain hundreds of genes.  This genetic variation is referred to as whole chromosome aneuploidy2-5. 
We note that “aneuploidy” in this dissertation refers to whole chromosome number variation without 
the inclusion of segmental chromosome aneuploidy.  By changing the dosage of many genes, aneuploidy 
leads to dramatic consequences.  
Early studies on aneuploidy related it solely to the disease state, which predicts that aneuploidy is unlikely 
to be persistent in the population as a result of the detrimental effect on fitness.  In recent years, the 
advent of genome technology, especially comparative genome hybridization and DNA sequencing, reveals 
a different picture (Table 1).  In lab strains of S. cerevisiae, it was estimated that 8% of the strains from 
the genome-wide ORF knockout library are aneuploid6.  In wild yeasts isolated from the environment such 
as oak tree soil, aneuploidy was also identified7.  In industrial strains, the deviation of DNA content from 
euploidy is a common feature documented decades ago8.  High-resolution genomic analysis techniques 
such as array-based comparative genomic hybridization (aCGH) and next-generation sequencing has 
revealed the detailed genome structure and copy number variation, which include whole chromosome 
aneuploidy, in strains used for diverse industrial applications, such as sake and beer brewing7,9,10, wine 
fermentation10, and sherry-wine aging11.  In pathogenic yeast/fungi, aneuploidy is associated with drug 
resistance2,12. For example, more than 50% fluconazole-resistant Candida albicans isolates from patients 
were found to harbor either whole chromosome or segmental duplication of Chr 513.  Whole chromosome 
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aneuploidy was also found in fluconazole-resistant strains of another pathogenic yeast, Cryptococcus 
neoformans14.  
 
Beyond yeast and fungi, aneuploidy has been documented in many other contexts.  It is long thought that 
due to their erroneous transmission during meiosis, aneuploid karyotypes are unlikely to be maintained 
during long-term adaptation and speciation in natural history.  However, this view of sexual reproduction 
barrier for aneuploidy is challenged by recent findings.  Leishmaniasis is a form of clinical pathology 
ranging from disfiguring cutaneous lesions to fatal visceral infection, caused by different Leishmania 
protozoan parasites associated with varied pathology features15.  Interestingly, it was found that four 
different Leishmanias have little variation in DNA sequence, yet exhibit dramatic difference in 
chromosome copy numbers16.  The aneuploid Leishmania can perform sexual reproduction nonetheless17, 
but the mechanistic details have yet to be elucidated. 
In multicellular organisms such as mammals, aneuploidy is present in both the germline and somatic 
tissues. Germline aneuploidy is rare and when present it causes severe developmental abnormalities. In 
humans, chromosome number variation in fertilized oocytes causes rare birth defects such as Down’s 
syndrome (trisomy 21, incidence at 1 in 2,000 births), Edwards syndrome (trisomy 18, 1 in 6,000 births), 
and Patau syndrome (trisomy 13, less than 1 in 10,000 births).  However, it is intriguing that several studies 
reported that aneuploidy is highly prevalent in the early blastomeres of developing human or mouse 
embryos18,19, raising a question as to at what stage aneuploidy impairs developmental programs and how 
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aneuploid cells are cleared during later development.  On the other hand, aneuploidy in somatic cells is 
not rare at all.  Aneuploidy is a hallmark of cancer, one of the leading causes of death. It is present in more 
than 70% tumors20-22.  Evidence indicates that aneuploidy may drive the tumorigenesis through its 
adaptive effect in a cell population.  But somatic aneuploid is not limited to cancer cells – work in recent 
years revealed that several normal human tissues bear a surprisingly high-level diversity of karyotypes.  
For example, normal human liver contains 25%-50% aneuploids23.  In the fetal brain, it was estimated that 
30-35% neurons are aneuploidy24,25. Compared with animal organisms, plant such as Arabidopsis thaliana, 
tolerates germline aneuploidy well and can cause substantial phenotypic variations26,27.  In summary, 
aneuploidy is observed from yeasts to human.  With the increasing application of quantitative DNA 
technology, it is likely that further evidence to emerge from diverse contexts illustrating the wide 
existence of aneuploidy.  
Why is aneuploidy, which defines an “abnormal” genome, widespread in 
nature?  
 
1) “Abnormal” karyotypes can be beneficial under abnormal environment. 
The effect of aneuploidy on fitness is context specific3.  Aneuploidy is thought to bring abnormality due to 
an imbalance in gene dosage.  It is assumed that the “normal” functionality of molecular complexes or 
pathways made of more loosely interacting molecules relies on the correct stoichiometry of their protein 
components.  When the normal stoichiometry is skewed, the functionality, such as efficiency, timing or 
specificity, of the system would be reduced or altered in someway.  However, normalcy is relative and in 
the context of physiology it refers to the preferred state or the state of highest fitness under a given 
condition.  Thus, a cell with a genome imbalanced (i.e. with suboptimal stoichiometry) for one condition, 
say the “normal” environment, may indeed have the altered functionality that gives rise to optimal fitness 
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under an altered, for instance, stressful condition3,28.   In many cases, the prevalence of aneuploidy as 
discussed above was found indeed in association with stress (Table 1).  For example, the wine 
brewing/aging process imposes potent proteotoxic stress due to high concentrations of ethanol and 
acetaldehyde11.  Fluconazole impairs the synthesis of ergosterol, an essential component of Candida 
albicans’ membrane29.  Even the normal tissue environment in an animal organism is usually repressive 
for cellular proliferation, which cancer cells must overcome (see following).  
The mechanism by which aneuploidy can bring adaptive phenotypic change has been extensively studied 
in single cell organisms.  In different manners, aneuploidy can cause expression change manifested on 
both mRNA1,6,28,30-33 and protein28,34 levels.  Although altered chromosome stoichiometry leads to 
expression changes of many genes, in some cases the adaptive effect of aneuploidy can be attributed to 
dosage change of a single gene.  For example, homozygous deletion of RPS24A gene on yeast Chr V causes 
a growth defect.  However, large, fast-growing colonies occasionally appear among a group of small 
colonies.  It was found that cells in these large colonies had gained a copy of Chr IX, carrying the RPS24B 
gene that is 97% identical in sequence to RPS24A6.  An advantage of achieving adaptive functions through 
aneuploidy over that through mutations of specific genes is that genes contributing to the same 
physiological outcome may be present on the same aneuploid chromosome, and this allows combination 
of adaptive dosage changes of two or several genes through a single chromosome dosage change.  In C. 
albicans, the fluconazole resistance associated with Chr V duplication can be mimicked by increasing the 
dosage of ERG11 (encoding the drug target) and TAC1 (encoding a regulator of the drug efflux system), 
which are both located on this chromosome13,29.   
The dosage change of genes located on an aneuploid chromosome can also bring adaptive traits by 
altering the expression of genes on other chromosome.  Myo1 is a motor protein required for constriction 
of the bud neck during cytokinesis, whose gene deletion leads to cytokinesis failure and in most cases 
lethality35.  In the rare Δmyo1 survivors, some are able to restore cytokinesis through gradual thickening 
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of the cell wall at the bud neck.  In these adapted strains, the expression of several genes involved in cell 
wall biogenesis was increased up to 16-fold compared to that in the isogenic wild-type haploid strain.  
Interestingly, these genes are located on multiple different chromosomes, but a commonly amplified 
chromosome in these strains is Chr XVI.  It turned out that Chr XVI carries the genes encoding two 
upstream regulators of cell wall biogenesis, Rlm1 and its upstream activator Mkk2, a MAP kinase kinase29.  
Thus, through altering the dosage of regulatory factors aneuploidy can cause broad gene expression 
changes well beyond a direct DNA dosage effect.  
Even though aneuploidy can bring adaptive traits into the population, it is also noticed that in any given 
environment, such as the presence of proteotoxic stress1,36 or a DNA damaging agent28,37, or low 
temperature28, most aneuploid karyotypes tested are not adaptive, but only some aneuploid karyotypes 
show enhanced growth compared to the euploid.  This reminds us of the fact that phenotypic changes 
generated by mutations are usually deleterious38; nonetheless mutations are a necessary ingredient of 
the force that drives adaptive evolution.  In other words, chromosome number variation or any other type 
of mutations does not guarantee enhanced cell fitness, but rather the adaptive value of genetic variation 
is best appreciated on the population level, where the adaptive variant is selected through competition.   
 
 
2) Aneuploidy impacts organismal versus cellular fitness differently in multicellular species. 
Despite evidence in unicellular organisms demonstrating how changes in chromosome stoichiometry 
bring about adaptation, it remains elusive whether similar mechanisms exist in metazoans.  It has been 
shown that aneuploidy leads to gene expression variation in mammalian cell lines in a manner similar to 
that in yeast32,33,39, but the counter argument has been that aneuploidy causes debilitating diseases such 
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as Down’s syndrome and cancer.  One way to reconcile this paradox is to distinguish cellular fitness from 
organismal fitness.  
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Figure 1.  Aneuploidy can exert opposing effect on overall body wellness and cellular fitness in disease.  
A: In tumorigenesis, the cellular fitness/proliferation of tumor tissue is enhanced at the expense of overall 
body wellness. B: Aneuploidy can have different roles on cellular versus organismal level. Organismal 
aneuploidy originates from karyotype alteration in parental germ line/gametes.  Cellular aneuploidy 
results from errors in somatic cell mitosis.  
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In natural history, the appearance of multi-cellularity loosed the tie between organismal evolution and 
celluar evolution.  The former considers relative fitness between individuals, whereas the later considers 
fitness between cells in the same individuals.  In order to survive organismal competition, strict 
developmental programs tightly control cell proliferation, death and morphogenesis in order to form and 
maintain homeostasis of functional structures.  Thus, organismal fitness occurs at the expense of the 
proliferative ability or even viability of individual component cells.   Oncogenic mutations, on the other 
hand, promote the cellular proliferation and survivability of cancer cells at the expense of the fitness of 
the host organism (Figure 1A). For example, the Ras protein, which controls cellular mitogenic signals, is 
mutated to hyperactive forms in 25% of cancers and renders abnormally high growth potential for the 
cancer cells harboring the mutations40.  The extrinsic barrier to cell proliferation, such as limited vesicular 
accessibility, can also be lifted by enhanced expression of VEGF in tumors40.  These examples highlight the 
apparent conflict between cellular versus organismal fitness.   
 
Whole organism aneuploidy such as Down’s syndrome originates from karyotype alteration in parental 
germ cells, which leads to drastic gene expression changes that disrupt the intricate developmental 
program evolved during long-term natural history, resulting in disease of the organism41.  On the other 
hand, tumorigenesis involves fierce selection and competition between normal cells and cancer cells as 
well as between cancer cells of diverse karyotypes42,43. As the tissue environment for cancer cells is hostile, 
this presents the natural selective force for different types of genetic variants that could survive and 
improve the fitness of the cell population at the expense of organismal fitness.  As the well known cancer 
hallmark, karyotype abnormality is a major source of genetic variation in cancer 21,44.  
The direct causative relationship between specific karyotype and overproliferation phenotype of tumor 
has been captured in a handful cases (Figure 1B). Trisomy 8 was observed in 12% of human acute 
promyelocytic leukemia (APL) 45,46.  It was long speculated that trisomy 8 brings the growth advantage 
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through introduction of an additional copy of the oncogene, MYC.  Interestingly, in an APL mouse model, 
64% of the cases were trisomy for chromosome 15, which also contains the mouse MYC.  MYC retrovirus 
transduction facilitates myeloid leukemogenesis and suppressed gain of chromosome 15. Meanwhile, the 
induction efficiency for APL in MYC heterozygous background was reduced.  Remarkably, in MYC 
heterozygous mouse where APL was inducted, a preferential amplification of the chromosome 15 
containing the wild-type MYC, but not the one missing the gene, was observed. These data strongly 
suggest that the elevated copy number of MYC through aneuploidy directly participates in the progression 
of APL47.  Another case comes from the well-characterized Down’s syndrome-associated predisposition to 
leukemia. Down’s syndrome patients have a reduced incidence of most tumors compared with euploid 
population48,49, but their incidence of pediatric acute megakaryoblastic leukemia (AMKL) is increased 500 
times50. Accordingly, the mouse model of Down’s syndrome, which contains trisomic chromosome region 
syntenic to human chromosome 21, also shows excessive cell proliferation in myeloid linage, which may 
progress into AMKL51.   Later, it was found that by deleting the trisomic copy of Erg, a transcription factor 
necessary for platelet development and stem cell function, the myeloproliferation was restored to 
normal52.  This case highlights that a karyotype (trisomy 21) that is detrimental in organismal level, can 
nontheless increased fitness and proliferation at cellular level under certain context (Figure 1B).   In spite 
of a few well-studied cases, the direct causative link between karyotype and tumor phenotype in many 
cases remains elusive due to the high level karyotype complexity associated with even a single cancer.  
This may reflect the existence of different ecological niche in a tumor 42.  In addition, different karyotypes 
can bring adaptation to the same stress, as shown recently in budding yeast28,30.  The tools that monitor 
the karyotype in single cell level, such as spectral karyotyping (SKY) or single-cell sequencing53, will provide 
insight into how karyotype heterogeneity evolves during the tumor progression or cancer treatment.  An 
ability to dissect the contribution of specific karyotypes to tumor phenotypes in a karyotypically 
heterogeneous population will be crucial for understanding the role of aneuploidy in tumorigenesis.   
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Chromosome instability can be induced by stress 
 
The broad existence of aneuploidy raises the question: how are aneuploids generated?  Mitotic error has 
long been known as a result of lesions in the genes controlling the chromosome segregation processes54,55.  
Genes that cause CIN when mutated are called CIN genes, many of which encode components of 
kinetochore, centrosome or mitotic checkpoint, which directly participate in chromosome segregation 
process.  In mammals, there is considerable evidence CIN gene mutations are tumorigenetic, even though 
the exact tumorigenetic karyotypes that arise in the presence of these mutations have not been identified.  
For example, Mad2 overexpression in mouse, which delays mitotic progression, promotes the occurrence 
of aneuploidy and leads to a wide spectrum of tumors56.  Human genetics also discovered mutations in 
checkpoint component BUB1B57, or centrosomal protein CEP5758 cause mosaic variegated aneuploidy and 
hereditary cancer.  However, CIN that is too high can inhibit tumorigenesis. In mouse, the 
haploinsufficiency of CENP-E, a kinechore component, modestly increase CIN in various tissues59. It 
drastically increases the incidence of spleen and lung tumors in aged animals.  However, in liver, it inhibits 
the formation of spontaneous cancer.  As liver’s basal level of CIN is high60,61, it is speculated that CIN level 
that is too high to even maintain the tumorigenetic karyotype can suppress the tumor formation59.  
The intimacy between the appearance of aneuploidy and stress (table 1) raised the possibility that stress 
may be another way to induce the production of aneuploids.   In Chapter 2, using a selective-neutral 
artificial chromosome, I showed that environmental stress, especially Hsp90 inhibition, can induce the 
production of aneuploids. Importantly, as a consequence, the karyotype diversity potentiates the 
population adaptability to diverse environmental stress.  Karyotype diversity is an important property 
observed in certain pathogenesis process, such as tumor and candidemia, which endows the cell 
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population with superior adaptability against therapeutic regimes. I further investigated how to target the 
adaptability of heterogeneous aneuploidy populations, with the results presented in Chapter 3.     
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Chapter 2: The Production of Aneuploidy by Stress and Its 
Consequence on Adaptability 
 
Chen G, Bradford WD, Seidel CW, Li R. 2012. Hsp90 stress potentiates rapid cellular adaptation through 
induction of aneuploidy. Nature 482:246-50.  
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Abstract 
 
 
 Aneuploidy, a state of having uneven numbers of chromosomes, is a form of large-effect mutation 
able to confer adaptive phenotypes under diverse stress conditions2,3.  Here we investigate whether 
pleiotropic stress could in turn induce aneuploidy in budding yeast.  We show that while diverse stresses 
can induce an increase in chromosome instability (CIN), proteotoxic stress, caused by transient Hsp90 
inhibition or heat-shock, drastically elevated CIN to produce karyotypically mosaic cell population.  The 
latter effect is linked to an evolutionarily conserved role for Hsp90 chaperon complexes in kinetochore 
assembly62,63.  Continued growth in the presence of Hsp90 inhibitor resulted in emergence of drug-
resistant colonies with chromosome XV gain.  This drug-resistance phenotype is a quantitative trait 
involving copy number increases of at least two genes located on chromosome XV.  Short-term exposure 
to Hsp90 stress potentiated fast adaptation to unrelated cyto-toxic compounds through different 
aneuploid chromosome stoichiometries.  These findings demonstrate that aneuploidy is a form of stress-
inducible mutation in eukaryotes, capable of fueling rapid phenotypic evolution and drug resistance, and 
reveal a new role for Hsp90 in regulating the emergence of adaptive traits under stress.        
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How cells maintain stable phenotypes and yet can adapt to diverse stress conditions through heritable 
change is a question with broad implications in evolution and disease progression.  In prokaryotes, while 
the genome is propagated with high fidelity under normal conditions, extensive studies have 
demonstrated that different modes of genetic variation can be directly induced by stress, fueling stress 
adaptation 64.  Recent work has revealed that one form of adaptive mutation in eukaryotic cells is the 
alteration of chromosome copy number, or aneuploidy 2,3,28.  Aneuploid yeast has been observed in 
diverse laboratory3, industrial 7,10,11  and natural 7 environments.  Aneuploidy leads to expression changes 
of many genes at levels that largely scale with gene copy number changes, bringing about dramatic 
phenotypic variation in a karyotype-specific manner under diverse growth conditions 28.  These findings 
suggest that to maintain phenotypic stability, karyotype stability must be ensured, and indeed intricate 
mechanisms have evolved to achieve highly accurate chromosome segregation to prevent CIN during 
mitotic proliferation.  Furthermore, as aneuploids are known to exhibit growth disadvantage compared 
to euploids under stress-free conditions 1,28, the pre-existing karyotype diversity in a euploid population 
is likely to be limited for rapid adaptation when exposed to stressful environments. This raises the 
question of whether the cellular mechanisms ensuring chromosome transmission fidelity may be relaxed 
under stress, thus allowing the emergence of karyotypic diversity to fuel rapid cellular adaptation. 
To test whether stress conditions in general could increase the rate of whole chromosomal instability, we 
exposed haploid yeast cells to chemicals inducing various types of pleiotropic stress for 12-14 hours and 
quantified chromosome loss rate by using the selection-neutral, chromosome fragment (CF)-based colony 
color assay (Figure 1a, Figure 2 and page 97 appendix) 65.  This initial screen revealed that many stress 
conditions, including hydrogen peroxide (oxidative stress), cycloheximide (translational stress), 
tunicamycin (ER stress), etc., elevated the chromosome loss rate to a level similar to that caused by 
benomyl, a microtubule inhibitor (Figure 1a).  Surprisingly, radicicol, an Hsp90 inhibitor 66, was by far the 
most effective CIN inducer: the chromosome loss rate (7.4x10-2/cell division) was hundreds of times above 
the control (2x10-4/cell division), even at a radicicol concentration (10 g/ml or 27 M) with only minor 
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effect on growth (Figure 1a, Figure 3).  Quantitative PCR (qPCR) confirmed that red colonies induced by 
radicicol had lost the whole CF (Figure 4a).  Two of the 13 tested red colonies were confirmed to have also 
gained chromosome (Chr) X or Chr XI (Figure 4b, c).  
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Figure 1.  Diverse stress conditions, especially Hsp90 inhibition, induce chromosomal instability.   
(a) 
radicicol treatment (middle) or 90 sec heat shock at 50.9 oC.  White colony color indicates retentions of 
CF; red indicates CF loss. Down: CF loss rates during exposure to diverse stress were inferred from red 
colony frequencies normalized to that of the vehicle-control population. N.D.: increase not detected over 
control.  See Figure 2, 3.  (b) Deletion of HSP82 or STI1 sensitized the CIN-inducing effect of radicicol and 
macbecin II.  Red colony frequencies normalized to that of wild-type DMSO control were averaged among 
4 replicates, shown with standard error of the mean (SEM). *, p<0.05; **, p<0.01, two-tail t-test.  (c) 
Representative images showing kinetocore localization of Ndc10-GFP and Cep3-GFP under different 
18 
 
conditions as indicated.  Radicicol diminished Cep3-GFP localization at the kinetocore.  Scale bar: 2μm.  
See Figure 5 for additional images and quantification.  
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Figure 2. Experimental Scheme for measuring CF loss rates induced by diverse stress conditions. 
(a) The structure of the artificial chromosome. ARS: autonomously replicating sequence. The gene 
suppressing the red pigment accumulation (SUP11) is located on the short arm, while the long arm is 
composed of an additional copy of Chr III left arm (Chr III.L). (b) Cells carrying CF, which give rise to white 
colonies, were grown in the presence of a specific chemical at two sub-lethal concentrations (low and 
high, Figure 3) for 14-16 hour and then plated onto stress-free rich media (YPD). The OD reading of the 
liquid culture after incubation, total number of colonies on YPD plates and the number of red colonies, 
which lost CF, were recorded (Figure 3).   
20 
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Figure 3. Diverse stress conditions, especially Hsp90 inhibition, increase the red colony frequency.  
Top, the parameters of the colony color assay used to estimate the CF loss rate were reported. Bottom, 
red colony frequencies (number of red colonies over total colonies), were reported. Many stresses 
elevated CF loss rate.  The CIN effect usually came along with strong inhibition of cell proliferation.  
However, radicicol, a Hsp90 inhibitor, led to a CF loss rate ~300x higher than the vehicle control and ~20x 
higher than benomyl, with only relatively minor growth inhibition.  Data were normalized to vehicle-
control. N.D.: no detection of red colony frequency increase over control. 
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Figure 4.  Hsp90 stress induces whole chromosome aneuploidy. 
(a) Both arms of artificial chromosome were lost in red cells induced by 10μg/ml radicicol treatment. The 
copy numbers of chromosome 3L, which is present on both endogenous Chr III and the chromosome 
23 
 
fragment (CF), are shown in relative to Chromosome 3R.  The red color of the colony suggested the loss 
of SUP11.  The loss of both SUP11 (on the CF short arm) and one copy of Chr 3L (the CF long arm) suggested 
that the whole CF artificial chromosome was lost in red colonies.  Structure of CF is presented in Figure 
2a.  Data were obtained with the qPCR assay.  (b, c) Whole chromosome aneuploidy of other 
chromosomes was identified among the red colonies generated after the 10μg/ml radicicol treatment. (b) 
DNA flow-cytometry analysis of 13 different red colonies treated by radicicol is shown, in comparison with 
ones treated with vehicle control. No polyploidization was observed. (c) Comparative genomic 
hybridization results of a euploid control, colony 6 and colony 10 are presented with dots representing 
the probe intensity log2ratios over euploid.  Repetitive elements were mapped to show regions where 
the copy number cannot be inferred from aCGH data 21,22. 
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A similar aneuploidy-inducing effect was also observed with macbecin II, a structurally distinct 
Hsp90 inhibitor (Figure1b) 67.  Deletion of one copy of Hsp90 genes, HSP82 showed enhanced CF loss 
compared to the wild type in the presence of radicicol or macbecin II (Figure1b).  Interestingly, deletion 
of STI1, the yeast homolog of mammalian Hop and a  co-chaperone of Hsp90, resulted in significantly 
elevated CIN even at a concentration of radicicol too low to induce CIN on its own (Figure 1b, Figure 5a).  
Heat is a common environmental stress known to tax Hsp90 function 68.  Heat-shock for 90 seconds at 
50.9C induced subsequent CF loss at a rate comparable to that by pharmacological inhibition of Hsp90 
(Figure 1a).  These results confirmed that Hsp90 stress is a potent inducer of aneuploidy.  Hsp90 chaperon 
complexes are crucial facilitators of many cellular functions69.  Previous biochemical studies suggested 
that Hsp90 is important for the activation of Ctf13 and assembly of the CBF3 inner kinetochore complex 
62.  Most CBF3 complex components, as well as the two co-chaperones involved in Ctf13 activation, 
showed haploinsufficiency toward radicicol (Figure 5b).  Radicicol disrupted the kinetochore localization 
of Cep3 but had less effect on Ndc10, thus altering the stoichiometry of CBF3 complex at the kinetochore 
(Figure 1c, Figure 5c, d, e).  In addition to the CBF3 complex, Hsp90 interacts with several other pathways 
that could affect chromosome transmission fidelity, including the spindle assembly checkpoint 70 (see 
below).   
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Figure 5. Radicicol reduces Hsp90 function and impairs CBF3 complex assembly.  
(a) Δsti1 showed higher sensitivity than Δhsp82 to the presence of pharmacological inhibition of Hsp90.  
The maximum growth rate of wild type (WT), Δhsp82 and Δsti1 are shown.  Bar graphs show meanSEM. 
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n=4. (b) All but one components of CBF3 complex exhibited haploinsufficiency in the presence of radicicol. 
Sgt1 is the co-chaperone bridging the Hsp90-Sti1 complex to kinetochore 23.  Different strains were 
spotted at 10x serial dilutions from left to right. (c) Hsp90 stress disrupted the stoichiometry of 
kinetochore components. The localization of Ndc10-GFP and Cep3-GFP in different conditions is shown in 
a field larger than that in Figure 1c.  Scale bar =2μm.  (d) Quantification of the intensities of kinetocore 
GFP signals in anaphase cells under conditions as indicated.  Bar graphs show meanSEM.  n>20 
cells/strain/condition.  (e) The percentages of cells with discrete kinetochore localization of Ndc10-GFP or 
Cep3-GFP were quantified.  n>30 cells/strain/condition.  
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Hsp90 taxation has previous been proposed to impact evolution  by releasing phenotypic variation from 
pre-stored genetic diversity in the population and by transposon mobilization 69,71.  Does Hsp90 inhibition 
also promote adaptation through induction of aneuploidy?  As a first test, a diploid strain was grown in 
the presence of high concentration of radicicol and 3 largest radicicol-resistant (Radr) colonies were 
selected and reconfirmed (Figure 6a, Figure 7 and page 101 in appendix).  Karyotyping revealed that all 3 
Radr colonies were aneuploid with a dominant karyotype feature: all 3 Radr colonies, which adapted 
independently, contained one or two additional copies of Chr XV (Figure 6a).  A haploid Chr XV disomy 
strain, generated by genetic manipulation 1, also showed strong resistance to radicicol (Figure 6b).  A 
previous genome-wide screen identified a set of genes exhibiting haploinsufficiency toward macbecin II, 
among which 2 of the top genes are located on Chr XV: STI1 and PDR5, a pleiotropic drug pump 70.  We 
deleted a single copy of STI1 or PDR5 gene from Radr colony 3, trisomy for Chr XV.  Growth measurements 
showed that either deletion abolished more than 50% of the growth rate gained by Chr XV trisomy over 
diploid in the presence of radicicol (Figure 6c).  A single copy of STI1 and/or PDR5 was then introduced 
into the parental diploid strain.  An extra copy of each gene mildly but significantly increased radicicol 
resistance, but their combination drastically improved radicicol resistance (Figure 6c, Figure 8).  These 
results indicate that Chr XV gain directly confers radicicol resistance through increased copy number of 
STI1 and PDR5, and possibly also other genes carried on this chromosome (e.g., SGT1).   
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Figure 6.  Aneuploidy is the predominant genetic change conferring adaptation to radicicol  
(a) Left: Replating and growth of control (ctrl) or three adapted radicicol resistant (Radr) strains on 
100μg/ml radicicol plates after 3 days incubation. See the experimental scheme in Figure 7.  Right: All 3 
re-confirmed Radr colonies were aneuploids with different levels of Chr XV gain. Intensity log2ratios over 
euploid are shown.  Repetitive elements are shown as vertical lines.  (b) Haploid Chr XV disomy 
generated by genetic manipulation shows higher growth rate than euploid in radicicol.  (c) Increased 
gene dosages of STI1 and PDR5 encoded on Chr XV are partially required and sufficient for radicicol 
resistance.  The maximum growth rates were averaged for 4 replicates and normalized to diploid, shown 
with SEM.   
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Figure 7. Evolution experiment to select for stable radicicol resistant colonies 
Briefly, a diploid strain was first grown on plate containing high concentration of radicicol (100μg/ml) or 
vehicle control; three of the largest radicicol resistant colonies along with a colony from the vehicle 
plate were cultured overnight in drug-free media to wash out non-genetic effect and then retested for 
radicicol resistance (See page 101 for experimental details in appendix). 
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Figure 8. Increased gene dosages of STI1 and PDR5 encoded on Chr XV are partially required and 
sufficient for conferring radicicol resistance. 
Representative growth curves for the indicated strains in 100 μg/ml radicicol are shown.  
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We next tested if the karyotype diversity produced by Hsp90 stress-induced CIN could fuel adaptation to 
various other stress conditions.  A karyotypically mosaic yeast cell population (~1/3 of the population were 
aneuploid with different karyotypes, Figure 9c) was generated by growing a diploid strain under moderate 
Hsp90 stress (20μg/ml Radicicol) for 2 days.  This population was then tested for enhanced adaptability 
toward other stress conditions, including the presence of growth inhibiting concentrations of fluconazole, 
tunicamycin, or benomyl, over a control homogeneous euploid population (see experimental scheme in 
Figure 9a).  The radicicol-pretreated population did not show any growth advantage over the control 
diploid (vehicle pre-treated) on drug-free plates (Figure 10a, Ctrl).  However, on each of the different drug-
containing plates, the radicicol pre-treated populations demonstrated drastically enhanced colony 
viability and frequency to form large drug-resistant colonies than the vehicle-pretreated population 
(Figure 10a, b, c).  
Twenty one colonies were picked from the vehicle control plates bearing the radicicol-pretreated 
population, and out of these 12 were aneuploid, whereas none (0/9) from the control plate bearing the 
vehicle-pretreated population were aneuploid (Figure 10d, e, Figure 9d, e).  The vast majority (17/18) of 
the large colonies karyotyped from the drug plates bearing the radicicol-pretreated population were 
aneuploid (Figure 10e).  The drug-resistant colonies from the vehicle-pretreated population were also 
aneuploid (Figure 10d).  Importantly, the aneuploid colonies resistant to the same drug showed obvious 
karyotypic commonalities and tend to cluster together based on karyotype similarity (Figure 10e, Figure 
11).  For example, 4 of the 5 aneuploid colonies from fluconazole plates karyotyped gained an extra copy 
of Chr VIII, which carries Erg11, encoding an ergostrol biosynthetic enzyme known to confer fluconazole 
resistance in Candida albicans 29.  Losing a copy of Chr XVI is a predominant karyotype change among the 
tunicamycin-resistant colonies (seen in 10/12 karyotyped, Figure 10d).  Of the 12 benomyl-resistant 
colonies, 10 demonstrated karyotype clustering with 6 of them losing one Chr XII, but it appears that more 
than one karyotypic pattern could confer benomyl resistance.  This however is consistent with our 
previous observation of phenotypic convergence of distinct karyotypic patterns 28.  All the above common 
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karyotype features were significantly (Mantel-Haenszel tests) enriched in drug resistant colonies but not 
the starting radicicol-pretreated population prior to selection on drug plates (Figure 10d, e, Figure 9e), 
suggesting an association of specific karyotypes with resistance to certain drugs.    
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Figure 9. Moderate and short-term Hsp90 inhibition drastically increases the karyotype diversity in the 
population.  
(a) Experimental scheme to test the effect of moderate and short-term Hsp90 inhibition on the 
adaptability of population to new stresses. A diploid culture was established from a single colony and split 
into two groups, which are pretreated for 2 days with either vehicle control (V) or radicicol (R). They were 
then recovered in a drug-free environment for 24 hours to diminish non-genetic effects. The two groups 
were then plated on media containing 3 new stress-causing agents separately.  The experiment was 
repeated three times. (b, c) The population after moderate and short-term Hsp90 inhibition showed 
drastically higher karyotype diversity.  Immediately after the 2-day pre-treatment as mentioned above, 
the cell cultures treated by vehicle control (V group) or radicicol (R group) were plated onto YPD plates 
without drug.  Single colonies were karyotyped by qPCR. (b) The karyotypes of 6 colonies from V group 
were characterized showing all 6 remained euploid. (c) The karyotypes of 18 colonies from R group were 
characterized showing 6 of the 18 were aneuploid with different karyotypes. (d, e) The karyotype diversity 
induced in radicicol pre-treatment was partially maintained after the recovery phase. The cell cultures 
pre-treated by vehicle control (V group) or radicicol (R group) were plated onto YPD plates with vehicle 
control after the recovery phase. (d) The karyotypes of 9 colonies from V group on vehicle control plates 
were characterized showing maintenance of euploidy. (e) The karyotypes of 21 colonies from R group on 
vehicle control plates are shown.  Compared with Figure 9c, the karyotype diversity was reduced. This is 
likely attributed to the competition between cells bearing different karyotypes during the recovery phase. 
All karyotypes in this figure were determined by the qPCR assay.  
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Figure 10. Prior Hsp90 inhibition potentiates adaption to other stress conditions through divergent 
aneuploid karyotypes 
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 (a) Plates of vehicle-pretreated (V) group and radicicol-pretreated (R) group on different media as 
indicated.  ~40 cells were plated on DMSO (Ctrl); ~40,000 cells were plated onto each drug plate. FL: 32 
(b) Quantification of the 
number of viable colonies.  Shown are mean+SEM from triplicate experiments.  (c) The sizes of all colonies 
(including both R and V groups) grown on each type of plates were measured.  The distributions of top 
10% largest colonies between the two groups are shown. *, p<0.05; **, p<0.01, two-tail paired t-test.  (d) 
The karyotypes of 6 V colonies from 3 replicate experiments of each type as determined by qPCR 6. (e) 
The karyotypes of 6 independent R colonies from 3 replicate experiments of each type determined by 
qPCR. Arrowheads point to aneuploid chromosomes whose gain or loss frequency among resistant 
colonies was significantly higher than the starting populations (p<0.01, Mantel-Haenszel tests).   
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Figure 11. Independent drug-resistant colonies formed in the same new environment tend to share the 
same karyotype   
Resistant colonies formed in the same stress tend to be clustered together by their karyotype.  Two major 
clusters, containing resistant colonies to tunicamycin and benomyl, respectively, are highlighted by bars. 
The hierarchical clustering was performed in R using the complete linkage method using the Euclidean 
distances.     
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Figure 12.  Karyotype requirement and dynamics associated with tunicamycin resistance.  
(a, b) Chr XVI monosomy (small colonies (arrow)) is unstable and produces large euploid progenies 
(arrowhead).  Shown are a representative image of the colonies (observed after 3 day growth on YPD) (a) 
and karyotypes of the Parent A and the progeny colonies (A1-3) determined by qPCR (b).  (c) Chr XVI 
monosomy progenies (A1 and A2) but not euploid progeny (A3) displayed tunicamycin resistance.  Note 
that the size difference between small and large colonies on control plates was no longer apparent after 
7-day growth.     
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To further assess the selective advantage of aneuploidy and karyotype dynamics under varying stress 
levels, two single Chr XVI monosomy colonies from a tunicamycin plate were streaked on drug-free plates.  
Colonies of two distinct sizes emerged, with the small ones being predominant (Figure 12a).  Karyotyping 
showed that the small colonies represented Chr XVI monosomy, whereas the rare large colonies had 
gained back the missing Chr XVI and returned to diploid (Figure 12b, Figure 13a).  Tunicamycin resistance 
was tightly linked to Chr XVI monosomy: all of the small colonies were tunicamycin resistant while the 
growth of the big colonies was abolished by tunicamycin (Figure 12c, Figure 13b, c, d).    This result shows 
that an adapted aneuploid population also has the potential to return to euploid state when the stress 
condition is attenuated, suggesting that aneuploidy is not only a readily accessible mutation with large 
phenotypic impacts but is also reversible.  
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Figure 13. Chr XVI monosomy is unstable in stress-free environment and produces large (diploid) and 
small (Chr XVI monosomy) colonies  
(a) Colony size variation is due to karyotype instability of Chr XVI monosomy.  Shown here are karyotypes 
of the Parent B and the progeny colonies B1-3 as determined by qPCR karyotyping.  Sizes of these colonies 
on YPD plates are noted. See Figure 12 for similar result on Parent A lineage.  Parent A and B are direct 
progenies of the colony V-Tun-1a and 1b, respectively, in Figure 10. (b) Only Chr XVI monosomy progenies 
but not euploid progenies retain tunicamycin resistance.  Same numbers of cells were plated onto control 
and tunicamycin plates.  (c, d) Growth curves of the euploid progenies (A3 and B3) and the ChrXVI 
monosomy progenies (A1 and B1) in YPD liquid media containing vehicle (c) (d) 
are shown.   
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The results demonstrated that stress-induced chromosome instability, leading to aneuploidy, is 
a mechanism of stress-induced mutagenesis in eukaryotes with high adaptive value to diverse 
perturbations.  By far Hsp90 inhibition is the most potent inducer of aneuploidy among the stress 
conditions tested.  This may be due to a broad but critical involvement of Hsp90 in pathways 
governing chromosome transmission fidelity and cell division 70.  For example, the mitotic 
checkpoint gene MAD2 is a genetic interaction hub sensitive to Hsp90 perturbation 70. D2 
deletion was also sufficient to lead to rapid emergence of fluconazole-resistant colonies bearing 
an extra copy of Chr VIII 36.  As Mad2 requires the CBF3 complex for its activity at the kinetochore 
72, the exceptionally high-level CIN induced by Hsp90 inhibitors may be explained by a combined 
effect of interference with both kinetochore assembly and the checkpoint monitoring spindle 
defects.  It is presently unknown whether the other stress conditions induce CIN through similar 
or different cellular targets. 
The Hsp90 chaperon complex specializes in modulating the stability and function of many 
important regulatory and structural proteins 70.  As a result, Hsp90 acts as a capacitor facilitating 
evolutionary adaptation by unleashing the effects of pre-existing mutations when Hsp90 activity 
is taxed under mild stress 68,69.  Strong Hsp90 inhibition also induces phenotypic variation through 
transposon activation in Drosophila 71.  The results presented in this work reveal a new role for 
Hsp90 in adaptive evolution - as the guardian of chromosomal stability, the inhibition of which 
could trigger de novo karyotypic diversity leading to rapid adaptation through aneuploidy.  We 
note that our observed induction of aneuploidy required more potent Hsp90 inhibition than that 
required to reveal phenotypic effects of pre-existing mutations 68.  As the function of Hsp90 
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chaperon complex in kinetochore assembly is conserved in mammalian species 63,73, the Hsp90 
stress-induced aneuploidy may be a mechanism of cellular adaptation affecting a wide range of 
organisms.  
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Chapter 3: Target the adaptability of heterogeneous aneuploidy 
populations 
 
Chen G, Mulla WA, Kucharavy A, Tsai HJ, Rubinstein B, Conkright J, McCroskey S, Bradford WD, 
Weems L, Haug J, Seidel CW, Berman J, Li R. 2014 (under revision for Cell) 
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Abstract: 
 
Aneuploid genomes, characterized by unbalanced and diverse chromosome stoichiometry 
(karyotype), are associated with cancer malignancy and drug-resistance of human pathogenic 
fungi.  The phenotypic diversity resulting from karyotypic diversity endows the cell population 
superior adaptability to both natural stressors and clinical treatments.  We show here using a 
combination of experimental data and a general statistical model that the degree of phenotypic 
variation, thus evolvability, escalates with the degree of overall growth suppression irrespective 
of stress mechanisms. Such scaling explains the challenge of treating aneuploidy diseases with 
diverse different karyotypes by imposing a single mode of inhibition, yet specific karyotype 
features can be highly targetable.  Motivated by this finding, we propose an “evolutionary trap” 
targeting both karyotypic diversity and fitness of the population.  This strategy entails a selective 
condition “channeling” a karyotypically divergent population into one with a predominant and 
drugable karyotypic feature.  We provide a proof-of-principle test with mechanistic explanation 
in budding yeast and demonstrate the potential efficacy of this strategy toward aneuploidy-
based azole resistance in the human pathogen Candida albicans.  Targeting selected karyotypes 
may also be a viable approach for treating those tumors with a prevalent karyotypic signature.    
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Introduction 
 
Germline evolution shapes the organismal tree in changing environments during the long course 
of natural history, while acute environmental fluctuation drives asexual cellular evolution 42,74.  
Cellular evolution is often associated with dynamic structural changes in the genomes of 
microbes or cancer cells, allowing rapid adaptation to host defense mechanisms or the 
emergence of drug resistance.  Aneuploidy (chromosome copy number imbalance) is a type of 
genome alteration widely observed during cellular evolution of eukaryote species, such as 
laboratory 6,30,36, industrial 7,10,11,75 and pathogenic 13,14,76,77 yeasts, as well as protozoan parasites 
such as leishmania 78-80 and trypanosome 81,82.  Emerging evidence also points to aneuploidy as 
an important driver for the evolution of human cancer 44,47,52,83,84.   Due to its impact on the 
expression of many genes, aneuploidy brings about large phenotypic change that can be either 
detrimental or beneficial in a karyotype and environmental condition-dependent manner.  
 Aneuploid populations are often characterized by heterogeneity characterized by the 
coexistence of many different karyotypes.   Diverse stress conditions, such as Hsp90 chaperone 
taxation 36 and anti-fungal treatment 85 as well as stress caused by many gene mutations 55, 
elevate the rate of chromosome segregation errors and generate karyotypically and 
phenotypically divergent populations.  The resulting genetic diversity provides the raw material 
for evolutionary selection and endows the aneuploid population high adaptive potential 36,86,87.  
This underscores the exceptional challenge of treating disease-causing cell populations 
characterized by large karyotype heterogeneity and instability 53,85,88-90.   
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One idea that has been explored for potential therapy against aneuploid populations is to find 
drugs strongly exacerbating a common deficiency of aneuploids irrespective of specific karyotype 
91.   For example, a study found that, in a pool of aneuploid yeast strains each with a defined 
disomy karyotype, many showed prominent growth defect toward agents that perturb proteome 
homeostasis such as hygromycin B (a translation inhibitor) or geldanaycin (an Hsp90 inhibitor) 1.  
This was attributed to overloading of the protein quality control system as a result of excessive 
gene expression from the gained aneuploidy chromosome 34.  In support of this explanation, a 
broad signature of environmental stress response (ESR) was reported in the transcriptome of all 
disomy strains generated by genetic manipulation 1,92.  However, some of the disomy strains with 
ESR signature exhibited resistance, as opposed to sensitivity, toward proteotoxic agents, and one 
of the karyotypic features, increased copy number of chromosome XV (Chr XV), emerged as the 
adaptive variant when a diploid strain was evolved in the presence of a Hsp90 inhibitor (Chen et 
al. 2012a and also see Results of this study).  In addition, when a highly heterogeneous aneuploid 
population was treated with various drugs that imposed strong immediate inhibition, long-term 
culturing enabled evolutionary selection for a few variants that endured the initial suppression 
and then repopulated the population to render it drug-resistant 36.  These findings highlight the 
fallacy of short-term efficacy in drug treatments when dealing with heterogeneous populations 
already poised for rapid adaptation.     
In this study, we aim for an innovative approach that accounts for the evolutionary dynamics and 
achieves long-term growth suppression or extinction of aneuploid cell populations consisting of 
a wide spectrum of aneuploid karyotypes.  Our analyses show on a general level that a 
heterogeneous aneuploid population cannot be suppressed by a single type of stress condition 
but may become highly targetable once the karyotype diversity is drastically confined.  These 
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findings led us to design a two-component strategy targeting both the population’s adaptability 
and fitness.  We provide a proof-of-principle test of this strategy in the budding yeast and 
demonstrate its potential efficacy in dealing with aneuploidy-based resistance to fluconazole - 
the first-line drug against systemic fungal infection.    
 
Results 
Scaling of phenotypic variation with growth suppression under diverse stress conditions 
To investigate whether certain stress conditions may be consistently effective toward aneuploids 
with various karyotypes, we performed a re-analysis of the growth data from a previous study 
subjecting a panel of 38 aneuploid yeast strains (S. cerevisiae) with diverse and random 
chromosome stoichiometry to phenotypic profiling across a wide range of conditions with 
varying stress type and level 28.  Growth conditions were ranked by their general effectiveness 
toward the aneuploid strains as measured by the mean growth ratio relative to the euploid 
control (log2[aneuploid growth/ euploid growth]) (Figure 1A).  This analysis revealed a surprising 
trend: those conditions more toxic to the aneuploidy cohort (lower mean growth ratio) also 
produced a larger fitness spread among the aneuploids, such that even under highly toxic 
conditions (e.g. in the presence of 4-Nitroquinoline 1-oxide (4-NQO) or thiolutin), while many 
aneuploids failed to grow, some aneuploids endured or thrived.  The standard deviation (spread) 
and mean of the growth ratio (overall growth suppression) of diverse aneuploids are strongly 
correlated across diverse stress conditions (Figure 1B).  This same trend could also be observed 
with the set of disomy aneuploid strains isolated in a previous study 1 treated with increasing 
concentrations of different drugs (Figure 1C). 
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Figure 1. Scaling of phenotypic variation with growth suppression in aneuploids under diverse 
stress conditions.  
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(A) The growth of 38 aneuploid strains relative to the euploid, as log2ratio of aneuploid growth 
(OD increase) over the euploid (haploid, diploid or triploid) with the nearest ploidy, are binned 
by growth conditions and ranked by the average growth defect compare.  Each point in a box 
plot represents an aneuploidy strain.  The half-length of each box represents the standard 
deviation of relative growth among aneuploids and the middle line represents the average.  Note 
that the horizontal dashed line across 0 represents the euploid control, and under every 
condition there is a group of aneuploids with fitness close to or surpassing that of the euploid.  
(B) Phenotypic variation among the aneuploids, measured as the standard deviation of relative 
growth, scales with average growth defect of the aneuploid cohort across diverse stress 
conditions.  (C) The growth of 12 disomy strains relative to the haploid control under increasing 
concentrations of hygromycin B (Hygro), amphotericin B (Amph) or fluconazole (FL).  Box plot 
representation is as described for (a).  (D-E) Schematic representation of the model is shown for 
the simple case of N = 2. The distribution of the cell population on the X-Y dimension has a 
mountain-like shape due to normal distribution along the X and Y dimensions (shown in grey), 
representing activity distributions of two independent pathways across karyotypes.  The Z axis 
represents population density.  Deep blue to deep red code for increasing fitness. (D) Graph 
represents the stress-free condition, where the euploid is located at the center of the activity 
field (position m) assumes highest fitness.  (E) Graph represents a stress condition, where the 
optimal fitness point shifts from m to mk,l, reflecting the activity change necessary for adaptation. 
Consequently, the euploid (located at point m) no longer holds maximal fitness, whereas higher 
fitness is assumed by certain aneuploids (those occupying redder regions).  (F) Example 
simulation results of the model of 50 random aneuploids under diverse stress conditions 
(governed by varying type k and magnitude l) for a 12 dimension space (N = 12), with relative 
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growth displayed as the experimental data in (A). The red line shows the decrease of average log2 
growth ratio from the simulated aneuploid population.  Note the appearance of adaptive 
aneuploids under high-stress conditions (toward the right of the graph) and the correlation 
between the spread and growth suppression.  (G) Plots of model simulations demonstrating the 
scaling between mean and standard deviation of relative growth.  Each dot represents one stress 
condition from (F).   
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Figure 2. Additional Simulation Results and Experimental data for Diverse Aneuploids.  
For simplicity of visualization, a two-pathway (N = 2) system is shown in the schematic 
representation. (A) Schematic representation of a horizontal section (bottom graph) of the 2D 
distribution (top graph) under stress-free condition, as explained in Figure 1A.  Several different 
aneuploids located on the surface of the distribution within this section are shown along with the 
projected euploid and optimal fitness point m from the peak of the distribution.  Growth defect 
of aneuploids is represented by the length of fitness defect vector (Δd) within the plane of the 
cross-section. (B) Stress moves the optimal fitness center (mk,l) away from the euploid and 
increase the heterogeneity of fitness defect among aneuploids.  Δd is further subdivided into 
three variants: ΔdA denotes the fitness shift caused by aneuploidy under the stress-free condition;   
Δds denotes the fitness shift caused by stress;  ΔdA,S denotes joint effect of ΔdA and Δds, which 
reflects the distance between aneuploids and the optimal fitness center (mk,l) under stress 
conditions. (C-D) Example simulation results of the model of 50 random aneuploids under diverse 
stress conditions (governed by varying type k and magnitude l) for space with different number 
of dimensions.  The relative growth is displayed similarly as the experimental data in Figure 1A. 
The red line shows the decrease of average log2 growth ratio from the simulated aneuploid 
population.  Note the appearance of adaptive aneuploids under high-stress conditions (toward 
the right of the graph) and the correlation between the spread and growth suppression. (E-F) 
Plots of model simulations demonstrating the scaling between mean and standard deviation of 
relative growth given a range of N values.  (G) Experimental data shows that each aneuploid has 
its own weakness. The log2 ratio of growth of aneuploid strains, compared to corresponding 
euploid, under diverse growth conditions, were plotted and binned by strain ( as opposed to by 
growth condition in Figure 1A).  Note that, for vast majority of the 38 individual aneuploid strains, 
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there was at least one of the tested conditions causing an 80% or higher growth suppression 
compared to the euploid, suggesting that individual karyotypes are targetable.   
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We used a multi-dimensional statistical model to investigate the theoretical generality of the 
above experimental observation.  A simple schematic representation of the model is provided in 
Figure 1D and E and Figure 2A and B.  Briefly, we assume that fitness, as measured by cell growth 
in defined time in the experimental analysis, is governed by N independent pathways (e.g. energy 
production, DNA replication, mitosis, etc.), reflecting the modular architecture of cellular 
systems.  Given that aneuploidy affects the expression of hundreds of genes across the genome 
thus likely alters many components of each individual pathway, aneuploidy affects each pathway 
as a random process.  Thus, for each individual pathway, the distribution of pathway activity with 
diverse karyotypes assumes a simple normal distribution with the euploid located at the peak 
(corresponding to the mean).   Under the stress-free condition, the optimal fitness is reached by 
the euploid at the center and peak of the N-dimensional distribution (Figure 1D).  The fitness of 
an aneuploid population with any karyotype can be located in the N-dimension normal 
distribution at positions away from the peak, reflecting reduced fitness compared to euploid in 
the absence of stress.  In the presence of stress, however, the optimal fitness point moves away 
from the euploid position, reflecting changes in pathway activities needed for restoration of 
optimal growth, while the N-dimension normal distribution, determined by the genetic makeup 
of the cell population, remains the same (note that this model does not assume genetic changes 
under stress and thus examines the existing adaptability of the population) (Figure 1E).  The 
distance between the position of each karyotype (including the euploid) and the optimal fitness 
point represents the fitness reduction caused by stress.         
Simulation of this model with varying values of N and diverse types and levels of stress exerted 
on 50 random aneuploids revealed two properties of the system remarkably consistent with 
experimentally observed trends (Figure 1F,G).  First, under stress conditions with sufficient 
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magnitude (thus large mean growth suppression toward aneuploids), even though most 
aneuploids have lower fitness than the euploid, there were always a fraction of aneuploids 
assuming fitness positions closer to the optimal fitness point than the euploid.  The latter is 
reflected in the fraction of positive values of simulated log2 ratios of aneuploidy fitness over 
euploid fitness under a given stress condition.   Second, the absolute value of the mean and 
standard deviation of the fitness ratios satisfy a positive linear correlation across diverse stress 
conditions and a range of N values that specify the complexity of the growth control system 
(Figure 1F,G and Figure 2C-F).  The fact that such a simple model could qualitatively capture the 
experimental data suggests the observed phenomenon to be a general property of 
heterogeneous aneuploid populations irrespective of specific stress conditions applied.  It implies 
that the evolvability of karyotypically divergent populations escalates with increased stringency 
of growth inhibition. 
 The practical implication of the above finding is that any effective strategy against 
heterogeneous aneuploids must also target the population’s evolvability in addition to fitness.  
We reasoned that if a highly evolvable population with heterogeneous random karyotypes can 
be “channeled” toward a certain karyotypic characteristic under a designed selection (first 
treatment), thus drastically “shrinking” the population’s evolvability, a second treatment may be 
added to eradicate the selected singular or limited karyotypes.  Together these two treatments 
would form an “evolutionary trap” (ET) on the elusive aneuploid population.  Supporting this 
idea, our analysis illustrated that, in contrast to the aneuploid cohort with diverse karyotypes, 
each specific aneuploid has its own unique weakness: for a given specific aneuploidy strain 
among the 38 examined, one or multiple conditions could be found for most strains that caused 
growth inhibition over 80%  compared to the euploid control (Figure 2G).  
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Finding drugs forming an ET against heterogeneous aneuploid budding yeast  
We used the budding yeast as a model to investigate the validity of ET against heterogeneous 
aneuploids.  We first constructed a yeast population with high-degree karyotypic diversity by 
sporulation of a homozygous pentaploid yeast strain.  Previous work showed that nearly 100% of 
all variable spores resulted from meiosis of pentaploid cells are aneuploids with random 
chromosome stoichiometry and ploidies mostly in the range of 2-3N 28.  28 viable aneuploid 
meiotic products with ploidy above 1.9N (Figure 3) were mixed with isogenic diploid, triploid and 
tetraploid euploid cells in order to mimic karyotype heterogeneity observed in pathogenic fungi85 
or human cancers (97% of the 48,595 karyotypes recorded in Mitelman cancer cytogenetics 
database 20 were between 1.9N and 4N).  Because most aneuploid karyotypes obtained from 
meiotic segregation are unstable 28,93,94, the degree of heterogeneity of this mixed population is 
likely to be far beyond 31 (28+3) karyotypes, as shown by DNA content profiles of individual 
aneuploids collected (Figure 3).  We confirmed that this initial mixed population (referred to as 
“heterogeneous mix” for convenience) displayed a broad DNA content profile (Figure 4A) and did 
not show bias toward any specific chromosome gain or loss (Figure 4B,C).   
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Figure 3. DNA Content Profiles of 28 Aneuploid Strains Demonstrating Karyotype Heterogeneity 
Between and Within Individual Strains 
DNA content profiles of (A) Isogenic diploid (one representative figure of the two samples is shown) and 
triploid euploid control cells (B) 28 aneuploid strains by fluorescence-activated cell soring (FACS) are 
shown. On each profile, the G1 peak region (shown by the bracket) is defined by the G1 peak and its 
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surrounding area with the cell count higher than 10% of the peak position cell count. The mean and 
standard deviation of DNA content for the cells located in G1 peak region were calculated. Their ratio, 
coefficient of variation (CV), which reflects the internal karyotype heterogeneity within each strain, was 
marked.  For 20 out of 28 aneuploids with a CV significantly higher than the euploid control (z-test, p < 
0.05), a red star was marked.   
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To find a selective condition that could be used for channeling the diverse karyotypes toward a 
singular common characteristic, we took advantage of the previous finding that growth in high-
concentration of radicicol, an inhibitor of Hsp90 chaperone, selects for aneuploids gaining extra 
copies of chromosome (Chr) XV 36.  Treatment of three independent populations of the 
heterogeneous mix with 50 g/ml radicicol all predictably led to convergent evolution toward 
gain of Chr XV (Figure 4E), a signature enriched in neither the initial heterogeneous mix nor the 
non-drug control culture (Figure 4C,D).  We further karyotyped six individual colonies derived 
from a culture that had grown to saturation in racidicol-containing medium.  These colonies 
varied in both karyotype and ploidy but all shared Chr XV gain, confirming that radicicol caused a 
selective sweep in the heterogeneous mix (Figure 4F).  
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Figure 4.  Evolution in the Presence of High-concentration Radicicol Channels Diverse 
Karyotypes into Karyotypes with The Common Feature of Chr XV gain.  
A heterogeneous yeast population was constructed by mixing pentaploid meiotic progeny with 
different euploids (2n, 3n, 4n, each 10% at of total population).  (A) DNA content analysis of the 
heterogeneous mix compared to diploid by FACS.  (B) qPCR karyotyping of the heterogeneous 
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mix showing a lack of aneuploid karyotypic signature (thus euploid chromosome stoichiometry 
on the level of population average).  (C) The karyotypes of six individual colonies from the initial 
heterogeneous mix were determined by qPCR assay showing lack of common signature prior to 
drug selection. (D,E) The population average karyotypes of the heterogeneous mix evolved in 
YPD or the presence of 50 μg/ml radicicol are shown, respectively. (F) 6 colonies isolated from 
Rad Mix1 were karyotyped. Arrowheads point to the Chr XV gain, which occurred in all 3 
replicates of the heterogeneous mix cultured in liquid radicicol-containing media, as well as in all 
6 karyotyped colonies derived from the evolved mix. Karyotypes in B-F are presented in the form 
of chromosome dosage relative to basal ploidy.  The color key of heat maps color key is shown in 
B with blue representing loss and red gain. 
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  The above results indicate that radicicol imposes a strong selection for a highly specific 
and thus likely more targetable aneuploid population. We then performed a screen for chemicals 
particularly effective toward Chr XV trisomy - the selected karyotypic feature.  The growth of a 
Chr XV trisomy strain, in comparison to an isogenic diploid control strain, was assessed in the 
presence of a panel of 54 chemicals with previously verified potency against S. cerevisiae 95.   This 
screen identified hygromycin B, a translation inhibitor 96, as the most potent inhibitor of Chr XV 
trisomy relative to its effect on the diploid control (Figure 6).  We further confirmed potent 
growth inhibition by hygromycin B for all 6 different karyotypes identified from radicicol-selected 
cultures sharing Chr XV gain (as shown in Figure 4F) (Figure 5A).  It is important to note that even 
though hygromycin B effectively suppressed the growth of aneuploids that had gained Chr XV, 
this effect did not extend to all aneuploids.  In particular, aneuploid strains with increased Chr II 
or IX dosage, but having a basal dosage of Chr XV, were associated with superior resistance to 
hygromycin B compared to euploid control (Figure 5B,C).  Interestingly, the growth suppression 
by hygromycin B associated with Chr XV gain is dominant over drug resistance associated with 
Chr II or Chr IX gain, as strains with these features combined were highly sensitive rather than 
resistant to hygromycin B (Figure 5C).   
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Figure 5. Different chromosome gains associated with hygromycin B sensitivity or resistance 
(A) Six independent colonies isolated from radicicol-adapted population aneuploids with gain of 
Chr XV (as shown in Figure 4F) were grown under indicated conditions until saturation was 
reached in the fastest growing strain. Histograms show average amount of growth normalized to 
euploid and standard error of the mean (SEM) derived from 4 replicates.  (B) Chr II and Chr IX 
disomy strains generated previously by genetic manipulation1 exhibit resistance to hygromycin B 
yet are sensitive to radicicol. (C)  Aneuploid strains generated by random triploid meiotic 
segregation with indicated karyotypic features were culture in different concentrations of 
hygromycin B. Box plots show growth relative to the euploid control with each dot representing 
an aneuploid strain.  Karyotypes are categorized by their states of Chr II/IX/XV dosage, but other 
chromosome aneuploidy may also be present in these strains.  The amount of growth (OD 
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increase) was normalized to the euploid with the nearest ploidy. The dashed line represents the 
average of normalized controls (equals to 1). ** indicates p< 0.01 according to Mann-Whitney U 
test. 
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Figure 6. Drug Screen for a Chemical Specifically Targeting Chr XV Trisomy. 
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Diploid and Chr XV trisomy (with only Chr XV gain) were grown in YPD with 54 different chemicals 
at 4 different concentrations with concentration gradient from 0.05x to 1x. The 1x concentration 
is shown in the table. After overnight culture, inhibition of Chr XV trisomy compared to inhibition 
of the euploid was measured as  
𝐿𝑜𝑔2⁡[𝑂𝐷(𝐸𝑢𝑝𝑙𝑜𝑖𝑑)⁡ ⁡𝑂𝐷(𝐶ℎ𝑟⁡𝑋𝑉⁡𝑡𝑟𝑖𝑠𝑜𝑚𝑦)]⁄ , 
and shown in the heat map.  Arrowhead, hygromycin.  Arrow, radicicol.  
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We showed previously that dosage increase of STI1 and PDR5, two genes present on Chr XV, are 
“driver mutations” underlying Chr XV gain-associated radicicol resistance 36.   However, the 
hygromycin B sensitivity was unrelated to dosage alterations of these two genes (Figure 7A,B).  
To understand why Chr XV-gain aneuploids are hypersensitive to hygromycin B, each of the 453 
genes located on Chr XV with its original promoter and carried on a low-copy (centromeric) 
plasmid 97 was introduced into the diploid control strain and the growth was measured in media 
containing hygromycin B.  Of 7 hits that reached a Z score -1.96 or lower (Z-test, P < 0.05), 5 
plasmid transformants with genes located on Chr XV (CRS5, RPS15, TRM11, RRP6, SER1) were re-
tested and verified in individual growth assay (Figure 7C, Figure 8).  Furthermore, the integration 
of one copy of each gene associated with top 3 Z scores (CRS5, RPS15, TRM11) was able to 
partially recapitulate the hygromycin B-sensitivity of Chr XV trisomy in a diploid euploid 
background, demonstrating the strong dosage effect of these genes (Figure 7E).   
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Figure 7. Hygromycin B selects against and radicicol selects for copy number increases of 
different sets of genes located on Chr XV  
Copy number gain or loss experiments were performed to assess the impact of specific gene 
copy-number increase on hygromycin B sensitivity. The relative growth of different genetic 
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variants compared to the diploid euploid is reported in bar plots with the SEM derived from 3 
replicates.  Asterisks denote the genetic variants significantly different from the corresponding 
control background (the diploid euploid or the Chr XV trisomy (Tri-XV)) (*, p< 0.05; **, p<0.01; 
two-tail t-test).  (A-B) Copy number gain or loss assays showing that increased copy numbers of 
STI1 and PDR5, which are both critical for radicicol resistance, do not contribute to the 
hygromycin B hypersensitivity caused by the additional whole chromosome XV.  (C-D) Expression 
abundance is unlikely to explain the copy number effect of these genes towards hygromycin B.  
Each of 453 genes (available through MOBY library 97) located on Chr XV, along with its original 
promoter and carried on a CEN vector, was transformed into a diploid strain.  The mRNA (C) or 
protein (D) expression abundance of each tested gene in a wild type strain were mapped against 
its growth impact in the presence of 35 μg/ml hygromycin B, with Z scores denoting the deviation 
of growth of each strain from the population average. mRNA/protein expression abundance of 
genes was estimated using our RNAseq data (reads-per-million-per-kilobase, RMPK) or the 
published GFP measurement data 98.  Protein abundance data were not retrieved for 30% genes 
(including the hits CRS5 and RPS15). The grey area shows the 95% confidence interval for the 
linear fitting.  (E) Coy-number gain assays showing that the copy number increases of 3 genes 
(CRS5, RPS15, TRM11) on Chr XV were individually sufficient in a diploid euploid context to 
reproduce enhanced sensitivity to hygromycin B, but not radicicol resistance, contrasting copy 
number increase for STI1 and PDR5 as shown in A.  (F) Copy-number loss assays showing that 
deletion of none of the 3 genes (CRS5, RPS15, TRM11) rescued Chr XV trisomy from hygromycin 
B hyper-sensitivity.  In contrast, the deletion of either STI1 or PDR5 partially abolished the 
resistance of Chr XV trisomy to radicicol (B).  
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Figure 8. Increased Dosage of Individual Genes Located on Chr XV Causing Hygromycin 
Sensitivity in Diploid Yeast. 
A screen was carried out on a library of transformants in which the diploid euploid strain was 
transformed with low-copy number (centromeric) plasmids (from MOBY library) containing each 
of the ORF located on Chr XV driven by its original promoter. The growth was monitored in 
hygromycin (Methods and Materials).  (A) The seven hits from the screen which reaches 
statistical significance were retrieved from the library and retested in hygromycin.  The increase 
dosage of 5 genes (CRS5, RPS15, RRP6, TRM11, SER1) were confirmed to reproduce 20% or more 
hygromycin sensitivity exhibited by Chr XV trisomy in comparison to the diploid control. None of 
these transformants however reproduced the increase in resistance to radicicol as observed for 
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Chr XV trisomy (B). Increased sensitivity toward hygromycin due to copy number increased of 
CRS5, RPS15 and TRM11 (genes with top 3 Z scores from the screen) was further verified by single 
copy genomic integration as shown on Figure 7E.  Note: the concentrations of both radicicol and 
hygromycin were adjusted to produce growth delays for the diploid control with an empty MOBY 
(with URA marker) plasmid in SC-ura media with monosodium glutamate (MSG) as the nitrogen 
source (Methods and Materials) similar to the growth delay imposed on diploid in YPD media. 
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Hygromycin B as well as other proteotoxic agents were previously proposed to exaggerate the 
growth defect in aneuploids by augmenting the protein quality control deficit due to general 
imbalanced expression of large number of genes 1,99.  However, the verified genes whose dosage 
increase caused hygromycin B sensitivity were not highly expressed genes compared to the other 
genes located on Chr XV (p = 0.56 for transcripts, p = 0.43 for proteins, Mann-Whitney U test) 
(Figure 7C,D).  Of note, the top hit RPS15 encodes one of 30 proteins within the small ribosomal 
subunit to which hygromycin B binds 100, suggesting a direct gene-specific cause underlying the 
drug sensitivity.  Importantly, the dosage increase of Chr XV genes redundantly produced 
hygromycin B sensitivity, since the deletion of a copy each of the three hits (CRS5, RPS15, TRM11) 
individually did not change hygromycin hypersensitivity or radicicol resistance of Chr XV trisomy 
(Figure 7F).  Taken together, the mechanisms of radicicol-resistance and hygormycin-
hypersensitivity are attributed to different sets of genes located on Chr XV.  Furthermore, due to 
redundant effects and wide-spread gene locations (across both the left and right arms of Chr XV), 
an ET formed with radicicol and hygromycin B is not expected to be easily escapable through 
single-gene mutations or focal copy number changes.  
 
Evolution dynamics of cell populations under single-drug treatment vs ET 
Even though hygromycin B alone potently suppressed the growth of Chr XV trisomy strain 
initially, the treated cell population eventually adapted as indicated by growth takeoff after ~ 50 
hr (Figure 9).  Karyotyping of the adapted Chr XV trisomy culture revealed that the population is 
a mixture of euploid and aneuploid cells that no longer had Chr XV gain but some now carried an 
additional copy of Chr IX (Figure 9B,C), which was consistent with the result shown in Figure 9B,C.  
This observation reconfirmed the requirement for Chr XV gain in hygromycin B sensitivity and 
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demonstrated the ability of the population to escape single-drug treatment by continued 
karyotype changes.  As expected, the condition that selected for Chr XV, i.e. 50 g/ml radicicol, 
was highly toxic to all those survivors that had become hygromycin B resistant because they had 
lost the gained Chr XV (Figure 4D,E), supporting the rationale of combinatorial treatment with 
both radicicol and hygromycin B.   
Indeed, the combination of both drugs led to the extinction of all 3 independent cultures first 
subjected to the radicicol selection (Figure 10A-C).  The same drug pair was similarly effective 
against the heterogeneous aneuploid population (heterogeneous mix) when they were added 
simultaneously (Figure 10D-G, Figure 11).  It is important to note that the opposite effects of 
these two drugs on the fitness of a karyotype feature (Chr XV gain in this case) were key to their 
combined effectiveness (Figure 10D-G).  When the heterogeneous mix was treated with a single 
chemical, 10 out of 21 tested chemicals (for example, 0.08 μg/ml menadoine and 100μg/ml 
radicicol) imposed stronger growth suppression than 50 μg/ml hygromycin B (Figure 10F).  
Hygromycin B also ranked low among the drugs tested in suppressing euploid growth (Figure 
10D).  Yet, when combined with 50 μg/ml radicicol, hygromycin B, but not 0.08 μg/ml menadoine 
or 100μg/ml radicicol, led to the extinction of the heterogeneous mix (Figure 10G).  Thus, the 
opposing selective effects of these two drugs on the channeled karyotype (Chr XV gain) imposed 
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an adaptive dilemma for the heterogeneous population, leading to its extinction. 
 
Figure 9. Chr XV trisomy escaped growth inhibition by hygromycin B through loss of the gained 
Chr XV 
 (A) The growth (represented by OD reading on a Tecan reader) of both the euploid control and 
the trisomy XV strain was monitored in media containing 50 μg/ml hygromycin B. (B) The 
additional copy of Chr XV was lost in hygromycin B culture but not in YPD culture, as shown by 
the heat map of karyotyping result of the final culture. (C) Karyotypes of 6 single colonies from 
the trisomy XV culture in YPD or hygromycin are shown, three of which were re-tested for growth 
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in the presence of hygromycin B (D) or radicicol (E). Note radicicol sensitivity was re-established 
in all three adapted colonies from the trisomy XV culture in hygromycin, whereas isolates from 
the YPD culture remained radicicol resistant.   
  
76 
 
 
 
Figure 10. The combination of radicicol and hygromycin B extinct karyotypically heterogeneous 
population. 
(A-C) Combination of hygromycin B and radicicol effectively eradicates the radicicol-preselected 
aneuploid population. (A) Growth curves (as OD600 measured in Tecan) of the diploid control 
strain under conditions as indicated.  Note that 50 μg/ml hygromycin B alone had milder growth 
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suppression compared to 100 μg/ml radicicol.  (B) Growth curves of 3 populations preselected 
independently in the presence of radicicol (Figure 4E) under indicated conditions. (C) Growth 
curves of the same 3 populations as in (b) under indicated conditions where each drug was 
combined with 50 μg/ml radicicol. Each data point in B and C shows the mean and SEM from 3 
experiments.  (D-G) Combination of hygromycin B and radicicol effectively eradicates the 
heterogeneous mix.  Histograms show growth takeoff time, defined as the time it took for the 
designated cell culture to reach OD 0.2 (Tecan) under each growth condition.   
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Figure 11. ET Effectively Suppressing the Heterogeneous Aneuploid Population. 
Histograms show growth takeoff time, defined as the time it took for the cell culture to reach OD 
0.2 (Tecan readings) under each growth condition.  (A-C) three different cultures (euploid, 
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trisomy XV and heterogeneous mix) were treated with each chemical in single form, respectively. 
(D) The heterogeneous mix was treated with each chemical along with 50μg/ml radicicol.  (E) A 
list of the concentration of each chemical used. 
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An azole-based ET for human pathogen Candida albicans   
 It was previously shown that a mechanism for human pathogen Candida albicans to 
confer resistance to fluconazole, a first-line medicine treating invasive candidiasis in immune-
compromised patients, is gain of isochromosome 5L (i5L, which contains two copies of the left 
arm of Chr 5) 13. This aneuploid feature was also recapitulated in a laboratory evolution 
experiment selecting for fluconazole-resistant C. albicans 101.   We therefore tested the possibility 
of using the evolutionary-trap strategy for more effective anti-fungal treatment.  In this case, 
fluconazole serves as the “selection” drug, which would be used in combination with a second 
drug specifically targeting the i5L gain.  To this end, we screened a chemical library that contained 
1,713 FDA- or other regulatory agency-approved drugs, 580 natural compounds, and 420 other 
bioactive agents against an i5L-containing C. albicans isolate from a 30-year-old male who 
developed fluconazole-resistant candidemia, with its euploid derivative for comparison (See page 
117 in appendix for experimental design details) 13,102.  We looked for chemicals that show much 
elevated potency against the i5L-containing strain compared to the euploid control, since such 
drugs were likely to be missed in previous screens against C. albicans without the drug-resistance 
karyotype 103,104.    
A primary screen using a single concentration of 80 M for each drug found that 3.5% of the 
compounds (100 out of 2713, Figure 13A) caused at least 80% growth suppression to either the 
i5L strain or the euploid, or both.  For this set of compounds, we then profiled the drug-response 
curve for the pair of strains by growing them in a dilution series for each drug composed of 9 
different concentrations.  The concentration causing 80% growth suppression compared to 
solvent control (IC80) was determined for each drug and each strain.  Figure 12A shows that 
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chromosome i5L copy number difference caused considerable variations in fitness in the 
presence of these compounds.  In the presence of 26 or 11 conditions, the i5L strain showed 
significantly (Z-test, p < 0.05) higher (i.e., more resistant) or lower IC80 (more susceptible), 
respectively, than the euploid (Figure 12A).  As expected, the i5L strain, originally selected for its 
resistance to fluconazole, exhibited increased resistance toward a panel of 7 other azole 
derivatives approved by FDA.  The other end of the spectrum found pyrvinium pamoate (PP), a 
medication for pediatric pinworm infection (Figure 12A and Figure 13B). PP strongly suppressed 
the growth of the i5L strain at 10 M but was ineffective against the euploid at concentrations 
as high as 80 M after 48 hour culture on agar (Figure 12B).  Given the possibility that euploid 
and i5L-gained Candida could co-exist in patients treated with fluconazole 29, we tested the 
combinatorial effect of PP with fluconazole in a 1:1 mixed population of both karyotypes.  As 
shown in Figure 12C,D, at concentrations of PP that suppressed the growth of the i5L strain, the 
resistance to fluconazole regressed from > 256 g/ml back to the same level exhibited by the 
euploid without PP (32-48 g/ml), supporting the efficacy of the evolutionary-trap rationale to 
target the selected karyotype for combinatorial treatments.   
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Figure 12. Pyrvinium pamoate (PP) effectively targets the fluconazole-resistant Candida 
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aneuploid. 
(A) Relative IC80 (80% inhibitory concentration) of the diploid vs the i5L Candida strain for each 
of the hits of the primary drug screen.  Note that i5L strain displayed higher IC80 toward all 8 
anti-fungal azoles approved by FDA but much lower IC80 to pyrvinium pamoate (PP).  (B) Images 
of agar plates showing selective effectiveness of PP toward i5L candida.  (C) Resistance of the 
diploid, the i5L or the i5L+diploid mix population toward fluconazole.  The results of fluconazole 
Epsilometer test (e-test) are shown with the size of the halo indicating the level of drug 
sensitivity. (D) PP at concentrations above 10 M restored the sensitivity of the i5L+diploid mix 
population toward fluconazole in the e-test, in accordance to its singular form's activity against 
the i5L strain shown in B. Note even though the initial plating density was the same, due to the 
inhibition of the i5L cells, the overall growth was less in D compared to C.  Note that our euploid 
strain also exhibited a reduced susceptibility to fluconazole compared to the clinical E-test 
standard strain, which may be attributed to other point mutations (such as the hyperactive TAC1) 
within this strain 13.  All plate images were taken after 48-hour culture. 
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Figure 13. The Chemical Screen Searching for Chemicals Against i5L C. albicans. 
(A) The scatter plot shows the result of relative growth measurement of 2 strains (diploid and 
i5L) in 3,600 assay conditions at a chemical concentration of 80μM.  The assay number is higher 
than the total number of chemicals due to the partial overlapping between the chemical libraries 
used.  As the libraries used (the Prestwick and the Spectrum collection) partially overlaps, these 
conditions represents 2713 different chemicals, as judged by distinct CAS registry numbers.  119 
of the conditions, representing 100 distinct chemicals, caused an 80% or higher growth inhibition 
in at least one of the two strains tested. These hits are further categorized according to the strain 
toward which a chemical imposed 80% or higher growth inhibition.  (B) As the top hit from the 
chemical screen against i5L, the drug response for pyrvinium pamoate was assayed for both the 
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euploid and the i5L strain at 9 different concentrations ranging from 1 μM to 160 μM in 
duplicates.  The assay was carried in RPMI liquid media with 2% glucose added in 384-well format 
at 35 oC.  The relative growth of each strain compared to the corresponding drug-free control 
was recorded and plotted from 24-hour culture, and fitted with a four-parameter log-logistic 
function.  The average values from the duplicates are shown.  80% growth inhibition level is 
denoted by a dotted line. 
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Our experimental and theoretical findings argue on a general level that the difficulty of 
suppressing karyotypically heterogeneous cell populations is rooted in the large adaptive 
potential in the presence of severe stress.  ET deals directly with this difficulty by reducing 
karyotypic heterogeneity through an evolutionary process.  It is also motivated by the 
observation that even though no stress tested could kill all aneuploids in the population, the 
growth of specific aneuploids can be disproportionally inhibited or even eliminated under certain 
stress conditions.  In our proof-of-principle experiments in budding yeast, this common aneuploid 
feature is gain of Chr XV, which harbors the “driver mutations” for radicicol resistance (selection) 
and multiple “passenger” genes whose copy number increase redundantly confers sensitivity to 
hygromycin B, the agent for extinction (Figure 14A, see following).  The redundancy in genes 
whose copy number increase confers hygromycin B sensitivity and the requirement for multiple 
genes to achieve radicicol resistance predicted that escaping the trap is not easily attainable 
through single-gene mutations or copy number changes.  
This strategy of treating aneuploidy is distinct from the idea of targeting a single characteristic 
trait of aneuploids, presently thought to be the proteome imbalance overwhelming the protein 
quality control system 1,34,99,105.  We note that both drugs used in the yeast ET, radicicol and 
hygromycin B, could perturb proteome homeostasis 1,69,96,99, but the responses of aneuploids to 
these drugs are karyotype-specific rather than uniform.  Importantly, much of the hygromycin B 
hypersensitivity of Chr XV trisomy can be recapitulated with copy-number increase of a few 
specific genes producing only a small or even minute fraction of the expressed transcriptome or 
proteome from Chr XV.  In this case, the aneuploid karyotype alters fitness by perturbing specific 
pathways rather than augmenting a general deficiency of aneuploids, such as the overload of 
protein quality control system.  The rationale behind the dual drug treatments associated with 
87 
 
ET is also fundamentally different from the idea of synthetic lethality 106,107 or the use of dual 
drugs to target different aspects of the common defect of aneuploidy irrespective of the 
karyotype 105 , whose rationale is based on functional redundancy within an existing system 
without the anticipation of evolutionary changes.  By contrast, radicicol and hygromycin B, or 
fluconazole and PP, pairs of drugs forming ET do not interfere with redundant processes but 
rather collaborate to force and interject a predicted evolutionary trajectory of the genome, which 
involves changes in the copy number of a chromosome that links pools of genes regulating 
divergent responses to the different drugs (Figure 14A, B).  
Gain of Chr 5L is a genetic alteration prevalent in C. albicans with resistance to its first-line 
treatment, fluconazole13.  Through screen, the study found that PP, a FDA-approved chemical 
may be highly toxic to C. albicans strains with additional copies of Chr 5L.  Thus the combination 
of PP and fluconazole sets up an effective ET that may be able to eradicate the highly evovable 
aneuploidy C. albicans population in human patients.  ET may have the potential to be utilized as 
a novel strategy to treat aneuploidy diseases.  
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 Figure 14. Graphic Summary of the evolutionary trap (ET) 
(A) The molecular makeup of the yeast ET.  Radicicol selects for gain of STI1, PDR5 as well as other 
genes located on Chr XV, whereas hygromycin B selects against gain of TRM11, RPS15, CRS5 and 
other genes (e.g. SER1, RRP6. See Figure 8) which are also located on Chr XV.   For radicicol 
resistance, increased copy number of STI1 and PDR5 are driver mutations; in contrast, increase 
copy number of TRM11, RPS15 and CRS5 are passenger mutations, which are targeted by 
hygromycin B.  The positions of genes are placed according to their relative locations on the 
chromosome.  (B) The opposing selective effects of radicicol and hygromycin B on dosage 
increase of Chr XV impose an adaptive dilemma for the heterogeneous population with diverse 
karyotypes in budding yeast.   
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Chapter 4: Summary and Discussion 
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Summary 
 
Aneuploidy population is often presented with more than a single karyotype but rather a 
heterogeneous group of diverse karyotypes.  This is likely a consequence of how aneuploidy is 
generated, and the resulted heterogeneity can profoundly impact the cellular evolution process.  
In chapter 1, we showed that one consequence of strong Hsp90 inhibition, or in general CIN, is 
the production of a population with karyotypic diversity, which was shown in the study to 
promote rapid cellular adaptations to various stresses through karyotype selection.  The superior 
adaptability of a heterogeneous aneuploidy population likely underlies the clinical challenge in 
the treatment of different diseases driven by eukaryotic cellular evolution, such as candidemia 
or cancer.  In chapter 3, we proposed a novel strategy that eradicates the heterogeneous 
aneuploidy populations by targeting the trajectory of karyotype evolution and tested it in both 
lab yeast as well as the Candida clinical isolate. 
Our analyses started from an exploration of the general response of karyotypically 
heterogeneous cell populations to diverse stress conditions and proceeded to the design of a 
strategy to extinct such cell populations that accounts for their adaptive potential.  Our findings 
demonstrate that the phenotypic variation resulted from karyotype diversity of an aneuploid 
yeast collection scales directly with the degree of average population growth inhibition under 
diverse stress conditions.  Mathematical simulations based upon a few logical and statistical 
assumptions supports the generality of our experimental observation.  A more intuitive 
understanding of this phenomenon may lie in the highly pleiotropic nature of aneuploidy: as a 
result of its broad impact on gene expression, there is a high probability of a random aneuploid 
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karyotype to interact with a given stress condition, either exacerbating or alleviating the growth 
inhibitory effect of the stress.  Such tendency may contrast that of most single-gene mutations 
affecting only one or a small number of cellular pathways and are thus much more likely to be 
phenotypically neutral toward a given stress condition.   
The coexistence of karyotype heterogeneity and dominant karyotype features has been observed 
in both human cancer 4 and drug-resistant pathogenic fungi 13,85.  The prior selection that 
channels the karyotype change in these diseases may be leveraged as a part of an ET for 
therapeutic purpose. Our experiments with Candida provide a proof-of-principle case where PP, 
which selects against the gain of i5L, could enhance the efficacy of fluconazole, the prior selection 
favoring the gain of i5L.  PP is extremely well tolerated (5mg per kg of body weight) in pediatric 
population for gastrointestinal treatment due to the near-zero absorption rate 108.  Interestingly, 
vast majority cases of Candida infection occurs on the outer or inner surface of the body 109, and 
the origin of rare but life-threatening systemic Candida infection may be traced back to resident 
gastrointestinal Candida flora 110.  Thus, the strategy of augmenting azole with PP to treat 
Candida infections is worthy of investigation in clinics.   
 
 
Future Directions 
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Aneuploidy has been observed and documented in cancer more than a hundred years ago 111.  
Recent genomics data reinforced the notion that aneuploidy is widespread in human cancers4,112.  
Statistical analysis on published data also found that a vast majority of solid tumors are 
aneuploid: 91.7% of 817 solid tumor cell lines surveyed by Cancer Cell Line Encyclopedia (CCLE) 
have at least 1 arm-level copy number variation, whereas 58.9% have more than 10.  Yet, it 
remains elusive on how to target this hallmark of cancer.  The large karyotype heterogeneity 
existing even in a single tumor further complicates the strategy design to use aneuploidy as a 
drug target. One proposal views aneuploidy as a group of mutations sharing similar molecular 
feature. For example, the excessive protein produced by the imbalanced chromosome may cause 
a universal proteotoxic stress response among aneuploids.  And by extraggerating the 
proteotoxic stress, the growth of all aneuploids may be severely impaired1,32,34,91,92,99,105.  
 Using budding yeast as the model organism, my current study challenged this view by showing 
that the phenotypic variation scales with the overall growth inhibition in the heterogeneous 
aneuploidy population (the scaling).  A general multi-dimensional statistical model can produce 
similar behavior, suggesting the multi-pathway control of cellular growth may underlie the 
scaling.  The scaling predicts that a single stress can hardly eliminate a heterogeneous aneuploidy 
population.  Whether the scaling phenomena also exists in higher organisms remains unknown.  
It is of particular interest to investigate whether the scaling between phenotypic variation and 
overall growth inhibition exists in the population of cancer cells with diverse aneuploidy 
karyotypes.  Such scaling can release phenotypic variation upon stress, thus enabling rapid 
cellular evolution.  One way to examine such possibility is to leverage the widely available 
pharmacogenomics database in which a large number of cancer cell lines were tested against a 
wide spectrum of chemicals in different concentrations113-116.  By examining the relationship 
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between standard deviation and mean of growth rates of a population of cancer cell lines under 
different conditions, it should become clear whether the scaling similar to what we observed in 
yeast aneuploids also happen in human aneuploidy cell lines.  
If so, such observation will have a practical implication on how to target aneuploidy in cancer.  As 
shown in our yeast model, instead of targeting general aneuploidy, aneuploidy population would 
become more approachable by first channeling the population into the one with a dominant 
karyotype feature.  A second stress can then be applied to target the selected karyotype feature.   
Interestingly, it is noticed that in some of the tumors even before any chemical treatment, the 
karyotypes are heterogeneous but non-random: a dominant karyotype emerges during the 
tumor evolution process. Thus, the natural tumor evolution process can serve as the first 
channeling selection.  Under this condition, a chemical targeting the selected karyotype can set 
up an ET along with the tumor evolution.  For example, karyotype channeling happens naturally 
in tumors such as glioblastoma even without chemical treatment: Chromosome 7 gain was 
observed in 80% of tumor samples collected from The Cancer Genome Atlas Pilot Project (TCGA) 
cohort of 219 patients 117,118.  Within individual tumors, arm-level or whole chromosome gain of 
chromosome 7 was detected in nearly all surgical sections examined, suggesting this event, unlike 
other heterogeneous genetic alterations, is an early critical event in clonal expansion 119.  
Collectively, evidence at both inter- and intra-tumor levels suggest that the sweeping presence 
of karyotypic signatures in subtypes of tumors is likely to be a consequence of adaptation to the 
tissue micro-environment and/or the need for oncogenic transformation.  It is interesting to 
speculate that this natural karyotypic selection combined with drug treatment targeting the 
passenger gene dosage changes associated with the gained or lost chromosomes may form an 
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ET on this elusive disease while minimizing the damage to normal euploid tissues. In order to find 
such chemical it will be necessary to establish the correlation between specific karyotype and 
drug response.  One idea is to again utilize the cancer pharmacogenomic database consisting of 
both karyotype and drug response information.   
In summary, data mining on existing cancer cell line pharmacogenomics database may provide a 
viable path to expand the strategy of ET into the field of cancer biology.  Other experimental 
approach such as screening using a pair of euploidy and aneuploidy cells may also provide 
compound candidates which can be used to eradicate the dominant karyotype feature in cancer. 
Currently, the evolutionary trap strategy focuses on using two counter-acting compounds that 
select for and against the same karyotype feature.  However, genetic features beyond karyotype 
alterations, such as point mutations, may also be utilized to set up the ET.  
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Plasmids 
pRLB473, a pRS305 based plasmid, was constructed to integrate an additional copy of STI1 into the original 
locus and it was cloned as follows.  Primers Cp073 and Cp074 were used to amplify a fragment of DNA by 
PCR from budding yeast genomic DNA, containing the STI1 ORF and upstream/downstream sequences. 
This fragment was further amplified by using primers Cp078 and Cp079 to add a Not I cutting site to 5’ 
and a Xho I to 3’.   After restriction enzyme digestion, the fragment was inserted into pRS305. pRLB474, a 
pRS303 based plasmid, was constructed to integrate an additional copy of PDR5 into the original locus. 
Primers Cp057 and Cp058 were used to PCR-amplify a fragment of DNA from budding yeast genome, 
containing the PDR5 ORF and upstream/downstream sequences. This fragment was further amplified by 
Cp059 and Cp060 to add Not I to 5’ and Xho I to 3’, and inserted into pRS303.  The above plasmids were 
sequenced to verify the absence of mutations in the ORF, by using primers Cs10-Cs18 and Cs21-Cs23. 
 
Media 
 YPD media were made by mixing 10g Bacto-yeast extract (#212720), 20g Bacto-peptone 
(#211830), 20g Bacto-agar (#214010) together with 950ml water, autoclaved and adding 50ml 40% 
glucose.  After cooled to 60-65 oC, YPD was supplemented with 1% (v/v) DMSO or drugs dissolved in DMSO, 
and the plates were poured.  
 
Saccharomyces cerevisiae strains 
Standard techniques were used for yeast transformations.  STI1 and PDR5 were deleted in Chr XV trisomy 
strain as follows.  RLY6673, the Radr 3 in radicicol adaptation experiment with gain of only Chr XV, was 
streaked out from glycerol stock and karyotype-confirmed by qPCR.  To delete one copy of STI1, Cp027 
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and Cp028 were used to amplify the HPH gene, a hygromycin resistance marker, from a pFA6a backbone 
plasmid. A DNA fragment with the marker and 45bp homologous sequences flanking the upstream and 
downstream of STI1 was thus generated.  RLY6673 was transformed with this fragment to generate 
RLY7011 where one copy of STI1 was deleted by homologous recombination. To delete one copy of PDR5, 
Cp065 and CP066 were used following the same procedure as described above for STI1 deletion.  All 
deletions were verified by genomic PCR. As a previous report suggests transformation itself may induce 
aneuploidy 120, the karyotypes of the transformants were reconfirmed by qPCR karyotyping assay, and the 
ones retaining the original karyotype (Chr XV trisomy) were selected. 
To integrate one copy of STI1 into a haploid genome, RLB473 was linearized at BglII site and used to 
transform RLY2626.  RLY2626 is a meiotic progeny with the a mating type of the diploid strain RLY2628 
used in radicicol adaptation experiment.  The integration of one copy STI1 was verified by qPCR of genomic 
DNA using primers Cp088 and Cp089, yielding RLY7111.  To integrate one copy of PDR5 into RLY2627, a 
meiotic progeny with the  mating type of diploid RLY2628, RLB473 was linearized at SalI site before 
transformation.  The integration of one copy PDR5 was verified by DNA qPCR using primers Cp090 and 
Cp091, yielding RLY7114.  RLY7111 was then crossed with RLY2627 to generate RLY7147, an a/α diploid 
strain with one additional copy of STI1.  RLY7114 was crossed with RLY2626 to generate RLY7149, an a/α 
diploid strain with one additional copy of PDR5.  RLY7111 was crossed with RLY7114 to construct RLY7148, 
an a/α diploid strain with one additional copy of both STI1 and PDR5.  
 
Colony color assay for detecting CF loss induced by diverse stresses 
The CF is mostly a fragment of yeast Chr III, containing the left arm, the centromere, telomeres, and 
autonomous replication sequences 65.  It also contains SUP11 and URA3 marker on the right short arm.  
The transmission fidelity of the artificial chromosome was monitored by colony color.  The background 
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haploid strain carries an ochre ade2 mutation, ade2-101, and confers a red colony phenotype.  This red 
pigment accumulation can be suppressed by SUP11, carried on the CF, generating a white colony 
phenotype.  Chromosome loss events are manifested by the appearance of red colonies 54,121 .   
White colonies with CF (RLY4029) from YPD plates were used to inoculate overnight cultures in the -ura 
synthetic complete (SC) media grown 30oC. The culture was then diluted to OD600 0.1 in SC–ura media and 
grown for 6 more hours.  The cells were then transferred to YPD media at the initial OD600 of 0.2 containing 
either vehicle control (1% DMSO) or different stress reagents.  The cultures were incubated for 14-16 
hours at 30oC and final OD was recorded. Yeast cells were diluted to an appropriate density (determined 
in pilot experiments) and plated onto YPD plates.  After 3 days of incubation at 30oC, the plates were 
moved to cold room (4oC) to allow accumulation of red pigment for easy visualization.  Total and red 
colony number were recorded.  Due to the large number of plates, this experiment was performed in two 
batches with data combined.  
 
Estimating chromosome loss rate (γ) from red colony frequency (α) 
In order to estimate the chromosome loss rate (γ) per cell cycle, following parameters were measured: 
b: The initial background frequency of rare cells giving rise to red colonies in -ura culture.  To determine 
b, white cells with CF were cultured in SC-ura overnight and directly plated onto YPD plates. In 19608 
colonies counted, 12 colonies were found to be red, so the frequency of red cells in SC–ura culture was 
estimated to be 0.06%.  
n: The number of cell cycle in the liquid YPD media containing stress inducing agents or vehicle.  
n was estimated from OD reading, as  
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As the initial background frequency of rare red cells in SC-ura culture, b, can be expressed as: 
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Using the above model, the loss rate of CF in YPD with vehicle control is computed to be 2.1x10-4/division, 
similar to previous estimations based on sectoring assays 122,123.   
 
Colony color assay for detecting heat-shock induced CF loss 
RLY4029 (CF containing) cells cultured overnight in SC-ura media were transferred to YPD and OD adjusted 
to 0.5.  40l aliquots of the resulting culture were tranferred into PCR tubes and heat-shocked for 90s.  
The cultures were then cooled down to 23 oC.  600 untreated cells or 6,000 heat-shocked cells were plated 
onto YPD plates.  More heat-shocked cells were plated due to the high lethality.  After 3 days of incubation 
at 30oC, the plates were moved to cold room (4oC) to facilitate red pigment accumulation.  
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Imaging analysis of Ndc10-GFP and Cep3-GFP localization after radicicol treatment 
Yeast strains with C-terminal GFP tagging on NDC10 or CEP3 genes were retrieved from the GFP ORF 
tagging library 124.  All cultures were grown at 30 oC.  Both strains were cultured overnight in SC media and 
dilute to OD 0.1 and further grown for 3 hours.  The OD was again adjusted to 0.1 immediately prior to 
the addition of 1% Dimethyl sulfoxide (DMSO, vehicle control), 10 μg/ml radicicol or 100 μg/ml radicicol 
(final concentrations). After 4-6 hours incubations, Z-stack images were taken with an inverted Zeiss 200 
m outfitted with a spinning-disc confocal system (Yokagawa) and an EM-CCD (Hamamatsu C9100), using 
a 100x oil objective lens.   
 To measure the intensity of the dot-like kinetochore localization of GFP signals, only large-budded 
anaphase cells with two distinct dots per cell were included, as prior to anaphase, the kinetochore signal 
varies depending on the status of DNA replication.  Extraction of data from images was performed by 
Image J software.  The background was first subtracted. For cells within the central field of the image, a 
circle slightly larger than a normal dot was specified, where average fluorescence intensity was measured.  
The same circle was used for all measurements.  
Since at 100μg/ml radicicol, a large proportion of cells failed to localize Cep3 to the kinetochore, cells were 
scored for the presence of the Cep3-GFP or Ndc10-GFP kinetochore localization to distinguish cells with 
discrete dot-like GFP localization on kinechore from the ones with diffuse localization.       
 
Selection for radicicol resistant yeast colonies 
~600 diploid RLY2628 cells were plated onto plates containing 100 g/ml radicicol (1st drug pate) while 
10 fold fewer (~60) RLY2628 cells were plated onto plates with vehicle control.  At this radicicol 
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concentration the cell survival rate as measured by colony formation was ~7%.  After 7 days incubation at 
30 oC, 3 largest colonies from each plate were picked and cultured, for roughly 5 generations, in drug-free 
YPD media overnight until saturation. This step was designed to diminish adaptation through non-genetic 
changes.  The cultures were then plated again at ~400 cells/plate onto YPD media with radicicol (2nd drug 
plate) to re-test their drug resistance.  After 3 days incubation at 30 oC, the images were taken.  One colony 
randomly picked from each of triplicate of the 2nd drug plate was subjected to comparative genomic 
hybridization (CGH).  
 
Comparative Genomic Hybridization 
 Array construction and hybridization were carried out as described previously 125. The arrays 
consisted of 23.3k 70-mer custom oligonucleotides designed to tile the yeast genome with an average 
spacing of 528 bp. Genomic DNA was extracted using YeaStar™ Genomic DNA Kit (Zymoresearch), and 
then labeled for array analysis using the BioPrime Plus Array CGH Kit (Invitrogen). Data analysis was 
performed with the R programming language. Array intensities were background subtracted and 
normalized using the loess method from the limma package 126.  After global normalization, probe groups 
representing each chromosome were further adjusted by dividing each by the median of all 
chromosomes.  The karyotype for each chromosome was determined by the median log2(test strain/wt) 
for all probes representing that chromosome. For visualization, the data were then sorted by 
chromosomal position and smoothed using a running median with a window size of 7 probes. 
 
Quantitative growth Assays 
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 The quantitative growth assays were performed with a previously reported protocol127. Cells were 
cultured to saturation in YPD or SC-His+100μg/ml G418 (used for genetically constructed Chr XV disomy 
and the control euploid strains1) and then were dilute 100 times into YPD with either vehicle control or 
drug (such as radicicol or tunicamycin)-containing media and split into 4 independent cultures as 
replicates. The 96-well or 48-well plate (Falcon) was filled with 100l liquid and sealed with parafilm. The 
optical density (OD) at 595nm was continuously monitored at 30 oC using a Tecan Infinite M200 Pro. The 
data were extracted and analyzed by Magellan 7 software.  For growth assay on strains with a known 
aneuploidy karyotype, each strain was streaked into single colonies and karyotyped again right before 
growth assay to make sure that the tested strains retained the original karyotype.   
 
Determination of karyotype diversity caused by short-term radicicol treatment 
 All incubations were performed at 30 oC. RLY6864, a diploid strain in the same background as the 
CF strain was cultured in YPD overnight to reach saturation, diluted in fresh YPD and grown to OD 0.5. The 
cultures were then diluted to OD 0.05 in YPD media with 20μg/ml radicicol or vehicle control (1% DMSO).  
After 24 hours, the culture reached saturation and was diluted 100x and cultured further. The next day, 
the cultures were plated on YPD plates without drug to form single colonies, which were karyotyped by 
DNA qPCR. 
 
Flow cytometry analysis of DNA content 
 A protocol optimized from that previously reported128 was used to process yeast cells for DNA 
analysis by flow cytometry with improved ploidy resolution and throughput.  As the purpose of this 
analysis was to identify changes in ploidy, cells were grown to saturation.  The cells were harvested, 
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washed once with water, and fixed in 70% ethanol in a 96-well plate for 1 hour.  Samples were then 
transferred into a 96-well polypropylene filter (Whatman), where the ethanol was removed by vacuum 
and the cells washed twice with water. 100 l 2mg/ml RNase (Sigma) solution was then added to remove 
the RNA.  After 2 hour incubation, 5mg/ml trypsin (Sigma) was added to digest the protein thoroughly.  
This procedure continued overnight at 37 oC and was the key for much improved DNA peak resolution 
over previous protocols.  The cells were then washed in 50mM Tris 7.5 buffer and sonicated.  2μM Sytox 
Green dye (Invitrogen) was added to stain the DNA.  The data was collected with the FITC channel on an 
Influx cytometer (BD Biosciences), and analyzed by Flowjo.  
 
 
Karyotyping yeast cells by DNA qPCR 
 The detailed protocol used to karyotype yeast cells by DNA qPCR has been described elsewhere 
28.  Briefly, a pair of qPCR primers was designed for each of the 2 pericentromeric regions flanking every 
centromere. By measuring the relative copy number of these pericentromeric DNA fragments through 
DNA qPCR in comparison to a known euploid strain, the number of each chromosome was determined.  
 
 
 
Testing the adaptability of the population with karyotype diversity induced by Hsp90 stress 
 The initial pre-treatment process was essentially the same as described in the short-term radicicol 
treatment. Three lines of independent cultures were established, each from a single colony and split into 
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two groups: one with 20μg/ml radicicol, the other with 1% DMSO control. After the karyotype diversity 
was generated, each line of culture was washed with YPD 3 times and then diluted 100x in YPD without 
any drug.  This recovery step lasted for 24 hours to recover from any non-genetic effects caused by 
radicicol pre-treatment. The cells were then plated either at 40,000 cells/plate onto new stress plates or 
at 40 cells/plate onto control YPD plates with 1% DMSO. The plates were incubated at 30 oC for around 7 
days.  
 The plates were imaged by using a scanner (HP Scanjet 4070) and colony number and sizes 
recorded using an automatic colony identification software - imageQuantTL. All the colonies formed under 
the same stress conditions were ranked according to their sizes.  
 
 
Assays to test the linkage between Chr XVI monosomy and tunicamycin resistance 
 Strain V-Tun-1a and V-Tun-1b were streaked out from glycerol stock into single colonies. From 
passage 1, one small colonies of each strain were karyotyped by qPCR and patched on YPD plates so that 
high density of cell colonies can form to enrich the rare big colonies.  The patches were further streaked 
out to single colonies.   
 Single colonies with different sizes were karyotyped by qPCR. Colony growth was characterized 
right after karyotyping by both colony formation on solid plates and growth curve in liquid media.  For 
colony formation assay, a portion of the fresh colonies were directly plated onto YPD plates with vehicle 
control or 2.5μg/ml tunicamycin at the same density of ~50 cells/plate.  The plates were incubated in 30 
oC for around 7 days before images were taken. Meanwhile, a small portion of colonies were cultured in 
YPD to saturation, karyotyped by qPCR again and then diluted 100x into YPD with either vehicle control 
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or 2.5μg/ml tunicamycin.  4 replicates of each colony from each condition were monitored for the growth 
by using a Tecan Infinite M200 Pro reader, as described above.  
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I. Strains and genetic manipulations 
 
Plasmids construction 
Plasmids used in this study are listed in Table S2 pGC881-883 were pRS306 based plasmids; constructed 
to integrate an additional copy of TRM11, CRS5, and RPS15 into the original locus in the yeast genome. 
Primers WMG61 and WMG62 were used to amplify the ORFs using respective plasmids from MOBY-ORF 
collection. These PCR amplified ORFs were inserted into EcoRI digested pRS306 using In-Fusion® HD 
Cloning Kit (Cat. # 638909). Primers WMG37 and WMG38 were used to verify the absence of mutations 
in the ORF of plasmids PGC881-883. pGC884 was a MOBY-ORF library plasmid without ORF. 
 
Saccharomyces cerevisiae strains 
Strains used in this study are listed in Table S1.  Standard techniques were used for yeast transformations 
and deletion129,130. RLY8338 and RLY8410 were derived by transforming pGC884 into RLY2628 and 
RLY6673 respectively. RLY8344, RLY8345, RLY8411, RLY8412, RLY8415 and RLY 8416 were derived by 
transforming RLY2628 with a MOBY-ORF library plasmid containing RRP6, TRM11, CRS5, RPS15, SER1 and 
RPS27A respectively. To verify the absence of mutations in RRP6, TRM11, CRS5 and RPS15, ORFs used for 
above transformations were sequenced using primers WMG37 and WMG38. In case of RRP6 two 
additional primers, WMG44 and WMG46 were used to cover entire region of the ORF. RLY8339 was 
derived from RLY2628 by replacing leu2-3 with HIS3 and used as a marker control for other strains with 
the HIS3 marker. RLY8340, RLY8343, RLY8346, RLY8413, RLY8414 strains were derived from Chr XV trisomy 
strain as follows. RLY6673 was streaked out from glycerol stock, grown at 23°C and karyotype-confirmed 
by qPCR karyotyping assay. One copy of respective gene was deleted by transforming RLY6673 with a DNA 
fragment containing HIS3 and 45bp homologous sequences flanking the upstream and downstream of 
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ORF. All deletions strains were verified by genomic PCR. The karyotype of the strains derived from RLY 
6673 were reconfirmed by qPCR karyotyping assay and the ones retaining the original karyotype (Chr XV 
trisomy) were selected.  
RLY8417 was constructed by transforming NcoI digested pRS306 into MATa strain RLY2626. Further, 
integration of one copy of URA3 was verified by qPCR of genomic DNA using primers WMG63 and 
WMG64, based upon copy number of Ampicillin.  To integrate one copy of TRM11, MfeI digested pGC881 
was transformed into MATα strain RLY2627; integration was verified by qPCR of genomic DNA using 
primers WMG67and WMG68, resulting into RLY8419. RLY8420 was constructed by transforming NruI 
digested pGC882 into MATa strain RLY2626; integration of one copy of CRS5 was confirmed by qPCR of 
genomic DNA using primers WMG69 and WMG70. One copy of RPS15 was integrated into MATα strain 
RLY2627 by transforming BclI digested pGC883 and integration was verified by qPCR of genomic DNA using 
primers WMG71 and WMG72, resulting in RLY8421. RLY8417 and RLY8420 were crossed with haploid 
strain RLY2627, to generate diploid strains RLY8431 and RLY8433, containing one additional copy of URA3 
and CRS5 respectively. RLY8419 and RLY8421 were crossed with haploid strain RLY2626, to generate 
diploid strains RLY8432 and RLY8434, containing one additional copy of TRM11 and RPS15 respectively.  
 
MOBY library transformation for Saccharomyces cerevisiae 
MOBY plasmid library which contains centromeric plasmids carrying individual ORFs in the yeast genome 
driven by respective native promoters was constructed by Charles Boone lab131 and resourced from 
Thermo Open System. For Chr XV, the library covered 465 ORFs out of 529 non-dubious ones (88% 
coverage).  MOBY ORFs-carrying E. coli were inoculated into 2ml Deep Well Plates containing 1.8 ml/well 
of LB + 5 μg/ml tetracycline, 100 μg/ml kanamycin, and 12.5 μg/ml chloramphenicol.  Plates were grown 
overnight in a New Brunswick Scientific shaking incubator set to 220 rpm and 37°C.  Following growth, 
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plasmids were purified using a Tecan EVO liquid handling robot and the Wizard Magnesil Tfx System (part 
# TB314) from Promega. 
The plasmids were transformed into the diploid wild-type strain RLY2628 following the standard high-
throughput transformation protocol using the robot Biomek FX. The transformants were spotted onto SD-
ura plates and incubated at 30°C for 3 days. 454 out of 465 plasmids (97.6%) were successfully 
transformed.   
 
II. Yeast and C. albicans growth and lab evolution experiments 
 
Cell culture media 
Budding yeast was cultured using standard media.  C. albicans cells recovered from frozen glycerol stocks 
were grown on YPD plate.  For bulk liquid culture prior to drug sensitivity assays, SC media with additional 
80mg/L uridine was used.  RPMI1640 + 0.165M MOPS buffer + 0.2% glucose without bicarbonate (Lonza) 
was used for 96-well culture according to the Clinical Laboratory and Standards Institute (CLSI) standard 
M27-A3. For 384 well cultures, additional 2% glucose was added to accelerate the growth. Agar plates 
were prepared using RPMI1640 with MOPS without bicarbonate powder (US Biological) supplemented 
with 2% glucose and 1.5% agarose, following the E-test strip manufacturer's guideline (bioMerieux).  
 
Chemical reagents 
Radicicol powder was purchased from AG Scientific.  Hygromycin B solution (100mg/ml) was prepared by 
media facility at Stowers Institute for Medical Research from powder purchased from Sigma.  Small batch 
to batch variations were noticed for hygromycin B and effective drug concentration was adjusted based 
124 
 
on the growth delay it causes. Effective 50 μg/ml hygromycin B in YPD causes the wild type euploid 
overnight growth rate to reduce 50% so that from the same initial OD, it takes twice the time for the 
euploid cells to reach saturation under 50 μg/ml hygromycin B compared to in drug-free media.  The 
hygromycin B solution was aliquoted and stored in -20°C.   Chemicals used in screening process are 
described later under the screening section. 
 
Flow cytometry analysis of DNA content 
A protocol optimized from that previously reported36 was used to process yeast cells for DNA analysis by 
flow cytometry with improved ploidy resolution and throughput.  As the purpose of this analysis was to 
identify changes in ploidy, cells were grown to saturation.  The cells were harvested, washed once with 
water, and fixed in 70% ethanol in a 96-well plate for 1 hour.  Samples were then transferred into a 96-
well polypropylene filter (Whatman), where the ethanol was removed by vacuum and the cells washed 
twice with water. 100 l 2mg/ml RNase (Sigma) solution was then added to remove the RNA.  After 2-
hour incubation, 5mg/ml trypsin (Sigma) was added to digest the protein thoroughly.  This procedure 
continued overnight at 37 oC and was the key for much improved DNA peak resolution over previous 
protocols.  The cells were then washed in 50mM Tris 7.5 buffer and sonicated.  2μM Sytox Green dye 
(Invitrogen) was added to stain the DNA.  The data was collected with the FITC channel on an Influx 
cytometer (BD Biosciences), and analyzed by using Flowjo software.  
 
Yeast karyotyping by DNA qPCR 
The detailed protocol for karyotyping budding yeast cells by DNA qPCR has been described previously28.  
Briefly, a pair of qPCR primers was designed for each of the 2 pericentromeric regions flanking every 
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centromere. By measuring the relative copy number of these pericentromeric DNA fragments through 
DNA qPCR in comparison to a known euploid strain, the number of each chromosome was determined.  
 
Growth assays for budding yeast 
Cells were inoculated in a 96-well plate in non-stress media (YPD or SC with the appropriate selective 
condition) at 30°C for 24 hours.  The cultures were then diluted 100 times and incubated for another 24 
hours to allow all strains entering saturation.  Aneuploid strains were cultured at 23°C before growth 
experiments, the incubation temperature was lowered to 23°C to minimize stress and the dilution factor 
was reduced to 10x so that all different strains can similarly reach saturation.  The OD of the cultures were 
taken on a Tecan M200Pro reader and adjusted by OD before the growth experiment. 100x dilutions of 
the pre-cultures were inoculated into the media with or without different chemicals in 96-well or 384-
well plate for growth profiling. 
For continuous OD monitoring, cultures were set up in a 96-well sealed with parafilm and loaded into a 
Tecan M200Pro reader. Orbital shaking was set to 336rpm and 1.5 mm in magnitude.  OD at wavelength 
595nm was taken every 15 minutes and analyzed using the Magellan 7 software (Tecan).  For cultures 
whose OD reading was taken intermittently every several hours, the plate containing the cultures were 
placed in non-shaking incubator within a wet chamber to keep the moisture and before each reading, the 
plate was agitated with a Microplate Genie (Scientific Industries Inc.) for 10 seconds. The OD at 
wavelength 595nm was recorded by a Tecan M200Pro reader and the data files were processed by R.  The 
growth assays lasted until the fastest grower reached saturation, at which time the last OD readings of all 
strains were recorded. 
The drug concentrations of hygromycin B and radicicol were adjusted for different media (e.g., 
YPD vs SC-ura) and/or the strain background, so that the wild-type control show the same growth 
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delay as was observed in YPD media contained the stated drug concentration.  The growth of 
genetic variants was normalized to the according wild-type controls. 
For quantitative growth measurement in liquid, OD readings less than 0.02 are not reliable.  Thus, any OD 
readings lower than this threshold were adjusted to 0.02 to avoid spurious log2 values.  
  
Growth assays of MOBY transformants with extra copies of genes located on Chr XV  
Transformants of 465 MOBY plasmids carrying Chr XV genes (testing strains) along with the control strain 
RLY8410(diploid wild-type strain RLY 2628 transformed with an empty MOBY plasmid pGC8410) were 
inoculated in SC-ura media in 96-well plate and cultured in 30 °C for 24 hours to reach saturation.  The 
cultures were diluted 100 times and grew further in the same condition for another 24 hours until all 
strains reached saturation. The first OD reading (time zero OD) was taken at this moment reflecting small 
variations in saturation OD among different transformants.  The saturated cultures were then diluted 100 
times into SC-ura media with MSG (monosodium glutamate) as nitrogen supplement with 35 μg/ml 
hygromycin B. This concentration of hygromycin B was used because it caused similar growth delay (as 
measured by the time it takes to grow from OD 0.05 to saturation) of the control strain to double in SC-
HIS+MSG media, comparable to the effect of 50μg/ml hygromycin B on the wild type control strain in YPD 
media. MSG was used in the SC-ura media to replace ammonium sulfate as the latter reduces the efficacy 
of hygromycin B probably due to high salt concentration, which was noted previously also for G418132.  
The growth assays were performed in 384-well plates, with the strains aligned in a way such that each 
testing strain was neighbored by the control strain.  OD readings were taken every 3-6 hours on a Tecan 
M200Pro reader until the control strain cultures reached saturation.  Data analysis was performed using 
R.  Several layers of normalization were performed. First, the growth of testing strains was normalized to 
the neighboring control strains to eliminate positional effect across the plate.  Second, the growth of 
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testing strains was also normalized to the time zero OD to adjust for the minor variations among the initial 
cell mass input. Third, the Z score was calculated for the growth of each testing strains to record its 
deviation from the mean value of growth of all testing strains on the same plate.   
  Zx =⁡
ODx-Mean(OD)
SD(OD)
 *SD and Mean were calculated for each plate. 
This step was taken because it appeared that the median growth value for testing strains varied from plate 
to plate and was unlikely to be driven by a biological process relevant to hygromycin B sensitivity. The Z 
scores were then ranked from low to high with the lowest Z-scores (negative) associated with genes 
whose increased dosage leads to the strongest growth inhibition by hygromycin B in the diploid context. 
Top hits were picked from the yeast-transformant library and verified in 4 replicates by using a 96 well 
plate growth assay. The identities of the plasmids were further verified by sequencing the plasmids 
extracted from the transformants. The verified hits were further tested by gain and loss-of-copy number 
assays after gene integration or deletion.   
 
Statistical analysis  
Scatter plot, linear fitting and correlation statistical analysis were all performed using R.  The GFP intensity 
data was downloaded from a previous publication98 and the gene IDs were matched with those 
corresponding to MOBY transformants growth data using R.  
 
Construction of and lab evolution experiments on heterogeneous aneuploid mix 
Euploid pentaploid RLY6959 was sporulated in the super sporulation media, as previously described28.  
Individual tetrads were dissected and 40 viable colonies were characterized for ploidy through FACS with 
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28 selected with ploidy higher than 1.9N.  The selected aneuploids were cultured to saturation in 
individual wells and then mixed.  We note that inherent instability of most of the aneuploid spores28,93 
was likely to lead to further population heterogeneity.  This mix was further supplemented with 10% 
diploid, triploid and tetraploid each to generate a heterogeneous population with diverse karyotypes and 
ploidies.   
For evolution in the presence of radicicol, the heterogeneous mix was inoculated in either YPD or YPD 
with 50 μg/ml radicicol after 1/100 dilution from the saturated pre-culture. The cultures were grown at 
30 °C for 4-5 days until the radicicol culture reached saturation.  After the lab evolution, the cultures were 
diluted and plated onto YPD plate without drug to allow single colony formation.  Both the liquid culture 
and 6 random single colonies from the radicicol culture were karyotyped. 
To test if the radicicol-selected population could be extinct with the addition of hygromycin B, the Radr 
populations 1-3 from the above lab evolution experiments were recovered from glycerol stocks and 
colonies were combined and precultured in YPD at 23°C, as described in "Growth assays for budding 
yeast".  Four pre-cultures (RLY2628 diploid and the Radr Mixes 1-3) were then inoculated into different 
conditions: YPD, or YPD with 50μg/ml hygromycin, 50μg/ml radicicol or both drugs together.  The growth 
was performed in a 384-well plate with 35 μl media per well at 30°C in a humidity chamber.  OD was 
monitored by using a Tecan M200Pro reader. 
 To test the effects of single and dual drugs on heterogeneous aneuploidy mix population, the 
drug-containing YPD media were prepared following the same procedure for screening for agents against 
Chr XV trisomy (see below) and kept frozen at -80°C.  Additional radicicol for the combinatorial treatment 
was added after thawing before the experiment.  Three saturated pre-cultures (RLY2628 diploid, RLY6673 
Chr XV trisomy and the heterogeneous aneuploid mix) were inoculated into different media by 100 x 
dilution into 384-well dish with 35 μl media per well. There were 2 replicates for each condition. The 
incubation was maintained in 30°C in a humidity chamber. The OD readings were taken by using Tecan 
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M200Pro and results were analyzed with R.  Linear fitting was done between the last reading time point 
with OD below 0.2 and the first reading time point with OD above 0.2 to determine the time that the 
culture reached OD 0.2, as the growth takeoff time.  
 
Lab evolution experiments to monitor the escape of Chr XV trisomy in hygromycin B-containing culture 
RLY6673 (Chr XV trisomy strain) and control diploid strain (RLY 2628) were cultured in YPD with 50 μg/ml 
hygromycin B.  The cultures were grown at 30 °C until the trisomy culture showed significant growth. The 
trisomy culture was then diluted and plated onto YPD plate without drug to allow single colony formation.  
Both the liquid culture and 6 random single colonies were karyotyped. 
 
Plating assays and E-test for C. albicans 
C albicans colonies, recovered from the glycerol stock, were first karyotyped with qPCR to confirm the 
correct karyotype. Colonies were then streaked out on a fresh YPD plate and incubated at room 
temperature for 48 hours to allow single colony formation.  ~2mm colonies were picked up, re-suspended 
in 1ml 0.82% sodium chloride solution with the final OD adjusted to 0.0005.  10 μl of the resulting 
suspension was plated to give rise to ~100 colonies per plate.  The plate was incubated at 35°C in a 
humidity chamber for 2 days before the images were taken. 
Cell resuspensions generated using the above procedure were adjusted to OD 0.02. The i5L and euploid 
strains were mixed 1:1 to make the “mix” cell population.  100 μl solution was plated onto each plate to 
reach 40,000 colonies per plate and the plate was allowed to absorb the excessive moisture at room 
temperature for 20 min. The E-test strips were applied according to the manufacturer's guideline 
(bioMerieux) and the plates were incubated in a wet room at 35°C for 48 hours before imaging. 
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III. Screens 
 
Screening for agents against Chr XV trisomy 
The 100x stock solution for each drug from various venders was prepared from the powder using DMSO 
or water or ethanol as the solvent. The stock was added into YPD media to make the YPD media with 
highest concentration possible for the drug, using robot Platemate Plus (Thermo Matrix). The YPD stock 
was further diluted, by robot Tecan EVO, into lower concentrations in YPD.  
The cells (the euploid RLY2628 and the Chr XV trisomy RLY6673) were inoculated into drug-containing 
media using the robot Biomek FX. The starting OD reading of the culture is 0.05. The euploid and the Chr 
XV trisomy were arrayed in 384-well plates so that they neighbored to each other to control for positional 
effect.  OD readings were taken by using a Tecan M200Pro reader. The data files were pooled and analyzed 
in R. The drug selectivity against Chr XV trisomy is defined as the log ratio at 17 hours (when both strains 
reached saturation under the non-stress condition): 
Log
2
⁡[OD(Euploid)⁡ ⁡OD(Chr⁡XV⁡trisomy)]⁄  
 
 
 
Screening for agents against euploid or i5L C. albicans 
To screen for compounds affecting the growth of euploid or i5L C. albicans in liquid culture, RPMI1640 
medium (with MOPS and 2% glucose without bicarbonate, Lonza) was added to 384-well V-bottom 
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microplates (Axygen).  Two libraries were used: the Microsource Spectrum Collection and Prestwick 
Chemical library133, containing 2320 and 1280 small molecules, respectively, with a total of 2713 unique 
CAS registry numbers included. The compounds were added to RPMI+MOPS without bicarbonate +2% 
glucose using a positive displacement syringe head on a Platemate Plus (Thermo Matrix) to generate 112 
μM stocks (60 μl total volume).  Plates were agitated on a plate shaker to mix and then centrifuged at 
1000 rpm for 5 min. Subsequently, media were mixed with disposable tips using a 384 air displacement 
head on Platemate Plus prior to pipetting 25μl of the stock into 384-well microplates with flat-bottom, 
round-shaped wells (Genetix).  DMSO (8 wells, 0.8%) controls as well as fluconazole controls at varying 
concentrations (16 μg/ml, 32 μg/ml, 48 μg/ml or 64 μg/ml final concentration) were included on each 
plate.   
Overnight cultures of C albicans strains in SC+uridine (the euploid and the i5L strain) were adjusted to the 
same OD600 and added into drug media by using a Thermo Matrix Equalizer multi-channel pipettor. 10 μl 
culture of 100 cells was added into each well containing 25 μl to bring the final concentration of each 
compound from 112 μM to 80 μM.  A total of 3600 assay conditions were distributed into 2 sets (one for 
the euploid and the other for the i5L strains) of 17 384-well plates with the edge wells skipped without 
cells. The plates were incubated in a humidity chamber at 35 °C with OD readings taken with a Tecan 
M200Pro reader.  The OD readings were analyzed in R.  Drugs that repressed the growth of either the 
euploid or the i5L strain for more than 80% compared to the non-drug controls were selected as hits for 
the second round of screening extending the assay to multiple concentrations (see below). 
Culture plates were prepared and incubated the same way as described above, except that each drug was 
assayed at 9 different concentrations ranging from 1 μM to 160 μM and two replicates for each strain and 
each drug were assayed.  The OD reading was taken at 24-hour and analyzed using R.  OD readings of each 
strain under a series of different concentrations of the same drug were normalized to the non-drug control 
and fitted by a four-parameter log-logistic curve using drc package in R133.  IC80 values derived from the 
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fittings were compared between the euploid and the i5L strain. Not all chemicals' drug response curves 
could be fitted and IC80 of these chemicals were missing. For example, flucytosine killed both the euploid 
and the i5L across all concentrations tested including the lowest at 1 μM.  
 
 
